JPH03279378A - Benzopyran derivative - Google Patents
Benzopyran derivativeInfo
- Publication number
- JPH03279378A JPH03279378A JP21353090A JP21353090A JPH03279378A JP H03279378 A JPH03279378 A JP H03279378A JP 21353090 A JP21353090 A JP 21353090A JP 21353090 A JP21353090 A JP 21353090A JP H03279378 A JPH03279378 A JP H03279378A
- Authority
- JP
- Japan
- Prior art keywords
- group
- cyano
- benzo
- dimethyl
- lower alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001562 benzopyrans Chemical class 0.000 title description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 57
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 55
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 50
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 14
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 13
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 8
- 125000006518 morpholino carbonyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])N(C(*)=O)C1([H])[H] 0.000 claims abstract description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 9
- 230000003213 activating effect Effects 0.000 claims description 8
- 108010083133 potassium channel protein I(sk) Proteins 0.000 claims description 7
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- -1 N-cyano-formimidoyl Chemical group 0.000 abstract description 73
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 6
- 239000012359 Methanesulfonyl chloride Substances 0.000 abstract description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 abstract description 4
- 102000004257 Potassium Channel Human genes 0.000 abstract description 3
- 108020001213 potassium channel Proteins 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 230000004913 activation Effects 0.000 abstract description 2
- 229940124630 bronchodilator Drugs 0.000 abstract description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract description 2
- 229910006080 SO2X Inorganic materials 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 53
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- 238000004519 manufacturing process Methods 0.000 description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- 125000004432 carbon atom Chemical group C* 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 238000002844 melting Methods 0.000 description 13
- 230000008018 melting Effects 0.000 description 13
- 235000002639 sodium chloride Nutrition 0.000 description 13
- 238000000034 method Methods 0.000 description 11
- 239000002904 solvent Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- DCTOHCCUXLBQMS-UHFFFAOYSA-N 1-undecene Chemical compound CCCCCCCCCC=C DCTOHCCUXLBQMS-UHFFFAOYSA-N 0.000 description 4
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- RTEXIPZMMDUXMR-UHFFFAOYSA-N benzene;ethyl acetate Chemical compound CCOC(C)=O.C1=CC=CC=C1 RTEXIPZMMDUXMR-UHFFFAOYSA-N 0.000 description 3
- MDHYEMXUFSJLGV-UHFFFAOYSA-N beta-phenethyl acetate Natural products CC(=O)OCCC1=CC=CC=C1 MDHYEMXUFSJLGV-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000010446 mirabilite Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000004703 alkoxides Chemical class 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 230000004531 blood pressure lowering effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000004673 propylcarbonyl group Chemical group 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- ZQXCQTAELHSNAT-UHFFFAOYSA-N 1-chloro-3-nitro-5-(trifluoromethyl)benzene Chemical compound [O-][N+](=O)C1=CC(Cl)=CC(C(F)(F)F)=C1 ZQXCQTAELHSNAT-UHFFFAOYSA-N 0.000 description 1
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 1
- SSORSZACHCNXSJ-UHFFFAOYSA-N 2-[2-(3,4-dichlorophenyl)-3-[2-(2-hydroxypropylamino)pyrimidin-4-yl]imidazol-4-yl]acetonitrile Chemical compound ClC=1C=C(C=CC=1Cl)C=1N(C(=CN=1)CC#N)C1=NC(=NC=C1)NCC(C)O SSORSZACHCNXSJ-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical class CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000006032 3-methyl-3-butenyl group Chemical group 0.000 description 1
- YZSCPLGKKMSBMV-UHFFFAOYSA-N 5-fluoro-4-(8-fluoro-4-propan-2-yl-2,3-dihydro-1,4-benzoxazin-6-yl)-N-[5-(1-methylpiperidin-4-yl)pyridin-2-yl]pyrimidin-2-amine Chemical compound FC=1C(=NC(=NC=1)NC1=NC=C(C=C1)C1CCN(CC1)C)C1=CC2=C(OCCN2C(C)C)C(=C1)F YZSCPLGKKMSBMV-UHFFFAOYSA-N 0.000 description 1
- ONPGOSVDVDPBCY-CQSZACIVSA-N 6-amino-5-[(1r)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-n-[4-(4-methylpiperazine-1-carbonyl)phenyl]pyridazine-3-carboxamide Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NN=1)N)=CC=1C(=O)NC(C=C1)=CC=C1C(=O)N1CCN(C)CC1 ONPGOSVDVDPBCY-CQSZACIVSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- ZOEGTCHMBZBJPL-UHFFFAOYSA-N 8ah-chromene Chemical compound C1=CC=CC2OC=CC=C21 ZOEGTCHMBZBJPL-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical class [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 208000016599 Uterine disease Diseases 0.000 description 1
- GHVZOJONCUEWAV-UHFFFAOYSA-N [K].CCO Chemical compound [K].CCO GHVZOJONCUEWAV-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006251 butylcarbonyl group Chemical group 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 159000000006 cesium salts Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000005394 methallyl group Chemical group 0.000 description 1
- ITYJDNHFRZSTJY-UHFFFAOYSA-N methanesulfonyl bromide Chemical compound CS(Br)(=O)=O ITYJDNHFRZSTJY-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004998 naphthylethyl group Chemical group C1(=CC=CC2=CC=CC=C12)CC* 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000005504 styryl group Chemical group 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
[産業上の利用分野]
本発明は、新規なベンゾピラン誘導体およびこのベンゾ
ピラン誘導体を有効成分とする医薬組成物に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to a novel benzopyran derivative and a pharmaceutical composition containing this benzopyran derivative as an active ingredient.
[従来の技術]
近年、高齢化社会が進むにつれて、重大な健康上の危険
の要因となる高血圧症が注目されており、この高血圧症
の治療剤として、多種多様の作用機序の薬剤が臨床的に
広く用いられている。今後は新しい、より優れた作用機
序のカリウムチャンネル活性化作用を有する降圧剤の開
発が期待されている。[Prior Art] In recent years, as the aging of society progresses, hypertension, which poses a serious health risk, has attracted attention, and drugs with a wide variety of mechanisms of action are in clinical trials as therapeutic agents for hypertension. It is widely used. In the future, it is expected that antihypertensive agents with a new and better mechanism of action for activating potassium channels will be developed.
[発明の目的]
本発明の目的は優れたカリウムチャンネル活性化作用を
有し、各種疾病の治療に有効な新規化合物を提供するこ
とにある。[Object of the Invention] An object of the present invention is to provide a novel compound that has an excellent potassium channel activating effect and is effective in treating various diseases.
[目的を達成するための手段]
本発明者らは、新規なベンゾピラン誘導体を合成し、こ
れらのカリウムチャンネル活性化作用について検討した
ところ、下記の一般式[I]で示されるベンゾピラン誘
導体が優れたカリウムチャンネル活性化作用を有し、例
えばこの作用機序による強力な血圧低下作用、気管支拡
張作用を有することを見出し、上記目的を達成するに至
った。[Means for Achieving the Object] The present inventors synthesized novel benzopyran derivatives and examined their potassium channel activating effects, and found that the benzopyran derivative represented by the following general formula [I] was superior. The inventors have discovered that it has a potassium channel activating effect, and has, for example, a strong blood pressure lowering effect and bronchodilator effect due to this mechanism of action, and has achieved the above object.
本発明のベンゾピラン誘導体は、一般式[I]2
−C=N
N
[式中、R1は水素、低級アルキル基、低級アルケニル
基、低級アルキニル基、ヒドロキシ低級アルキル基、低
級アルコキシ低級アルキル基、低級アルコキシカルボニ
ル低級アルキル基、ジ低級アルキルアミノ基、アラルキ
ル基、または基R3−CO−(基中、R3は低級アルキ
ル基、フェニル基、フェニル基が置換されていてもよい
低級アルケニル基または低級アルキニル基)を意味し、
R2は水素、低級アルキル基、低級アルコキシ低級アル
キル基、フェニル基、またはアラルキル基を意味し、Y
はシアノ基、/SSロジン子、ニトロ基、低級アルキル
基、低級アルキニル基、低級アルキルカルボニル基、低
級アルコキシ基、ジ低級アルキルアミノカルボニル基、
アリール基、低級アルコキシカルボニル基、カルボキシ
ル基、またはモルホリノカルボニル基を意味する。]
て示される化合物またはその医薬上許容される塩からな
ることを特徴とする。The benzopyran derivative of the present invention has the general formula [I] 2 -C=N N [wherein R1 is hydrogen, lower alkyl group, lower alkenyl group, lower alkynyl group, hydroxy lower alkyl group, lower alkoxy lower alkyl group, lower Alkoxycarbonyl lower alkyl group, di-lower alkylamino group, aralkyl group, or group R3-CO- (wherein R3 is a lower alkyl group, a phenyl group, a lower alkenyl group optionally substituted with a phenyl group, or a lower alkynyl group) ) means,
R2 means hydrogen, a lower alkyl group, a lower alkoxy lower alkyl group, a phenyl group, or an aralkyl group, and Y
is a cyano group, /SS rosin group, nitro group, lower alkyl group, lower alkynyl group, lower alkylcarbonyl group, lower alkoxy group, di-lower alkylaminocarbonyl group,
It means an aryl group, a lower alkoxycarbonyl group, a carboxyl group, or a morpholinocarbonyl group. ] or a pharmaceutically acceptable salt thereof.
本発明のベンゾピラン誘導体を表わす一般式[I]にお
いて、R+ 、R2、R3およびY中の低級アルキル基
としては、直鎖状または分岐状の炭素数1〜6のアルキ
ル基が好ましく、例えばメチル基、エチル基、n−プロ
ピル基、1so−プロピル基、n−ブチル基、5eC−
ブチル基、tert−ブチル基、ペンチル基またはヘキ
シル基が挙げられる。In the general formula [I] representing the benzopyran derivative of the present invention, the lower alkyl group in R+, R2, R3 and Y is preferably a linear or branched alkyl group having 1 to 6 carbon atoms, such as a methyl group. , ethyl group, n-propyl group, 1so-propyl group, n-butyl group, 5eC-
A butyl group, a tert-butyl group, a pentyl group or a hexyl group can be mentioned.
R1およびR3中の低級アルケニル基としては、炭素数
2〜6のアルケニル基が好ましく、例えばアリル基、メ
タリル基、クロチル基、1−メチルアリル基、プレニル
基、3−メチル−3−ブテニル基、3−ペンテニル基な
どが挙げられる。なお、R3中の低級アルケニル基にお
いては、フェニル基が置換されていてもよく、このよう
な低級アルケニル基としては、スチリル基、シンナミル
基などが挙げられる。The lower alkenyl group in R1 and R3 is preferably an alkenyl group having 2 to 6 carbon atoms, such as allyl group, methallyl group, crotyl group, 1-methylallyl group, prenyl group, 3-methyl-3-butenyl group, 3 -pentenyl group, etc. Note that the lower alkenyl group in R3 may be substituted with a phenyl group, and examples of such lower alkenyl groups include a styryl group and a cinnamyl group.
R1、R3およびY中の低級アルキニル基としては、炭
素数2〜6のアルキニル基が好ましく、例えばプロパル
ギル基、1−メチルプロパルギル基、2−ブチニル基、
1−メチル−2−ブチニル基、3−ブチニル基、2−ペ
ンチニル基、3−ペンチニル基などが挙げられる。なお
、R3中の低級アルキニル基においては、フェニル基が
置換されていてもよく、このような低級アルキニル基と
しては、フェニルプロパルギル基、フェニルブチニル基
などが挙げられる。The lower alkynyl group in R1, R3 and Y is preferably an alkynyl group having 2 to 6 carbon atoms, such as propargyl group, 1-methylpropargyl group, 2-butynyl group,
Examples include 1-methyl-2-butynyl group, 3-butynyl group, 2-pentynyl group, and 3-pentynyl group. The lower alkynyl group in R3 may be substituted with a phenyl group, and examples of such lower alkynyl groups include phenylpropargyl group and phenylbutynyl group.
R1中のヒドロキシ低級アルキル基としては、直鎖状ま
たは分岐状の炭素数1〜6のヒドロキシアルキル基が好
ましく、例えばヒドロキシメチル基、ヒドロキシエチル
基、ヒドロキシ−n−プロピル基、ヒドロキシ−1so
−プロピル基、ヒドロキシーn−ブチル基、ヒドロキシ
−5ec−ブチル基、ヒドロキシ−tert−ブチル基
、ヒドロキシペンチル基、ヒドロキシヘキシル基が挙げ
られる。The hydroxy lower alkyl group in R1 is preferably a linear or branched hydroxyalkyl group having 1 to 6 carbon atoms, such as hydroxymethyl group, hydroxyethyl group, hydroxy-n-propyl group, hydroxy-1so
-propyl group, hydroxy-n-butyl group, hydroxy-5ec-butyl group, hydroxy-tert-butyl group, hydroxypentyl group, and hydroxyhexyl group.
R1およびR2中の低級アルコキシ低級アルキル基とし
ては、炭素数1〜4の低級アルキル基に炭素数1〜2の
低級アルコキシ基が置換された低級アルコキシ低級アル
キル基が好ましく、例えば2−メトキシエチル基、2−
エトキシエチル基、3−メトキシプロピル基、4−メト
キシブチル基などが挙げられる。The lower alkoxy lower alkyl group in R1 and R2 is preferably a lower alkoxy lower alkyl group in which a lower alkyl group having 1 to 4 carbon atoms is substituted with a lower alkoxy group having 1 to 2 carbon atoms, such as a 2-methoxyethyl group. , 2-
Examples include ethoxyethyl group, 3-methoxypropyl group, and 4-methoxybutyl group.
R1中の低級アルロキシ力ルボニル低級アルキル基とし
ては、炭素数1〜4の低級アルキル基に炭素数1〜4の
低級アルコキシカルボニル基が置換された低級アルコキ
シカルボニル低級アルキル基が好ましく、例えばメトキ
シカルボニルメチル基、エトキシカルボニルメチル基、
メトキシカルボニルエチル基、エトキシカルボニルエチ
ル基などが挙げられる。The lower alkoxycarbonyl lower alkyl group in R1 is preferably a lower alkoxycarbonyl lower alkyl group in which a lower alkyl group having 1 to 4 carbon atoms is substituted with a lower alkoxycarbonyl group having 1 to 4 carbon atoms, such as methoxycarbonylmethyl. group, ethoxycarbonylmethyl group,
Examples include methoxycarbonylethyl group and ethoxycarbonylethyl group.
R1中のジ低級アルキルアミノ基の低級アルキル基とし
ては炭素数1〜4の低級アルキル基が好ましく、このよ
うなジ低級アルキルアミノ基としては、例えばジメチル
アミノ基、ジエチルアミノ基などが挙げられる。The lower alkyl group of the di-lower alkylamino group in R1 is preferably a lower alkyl group having 1 to 4 carbon atoms, and examples of such a di-lower alkylamino group include a dimethylamino group and a diethylamino group.
R1およびR2中のアラルキル基としては、炭素数1〜
6のアルキル鎖を有するアラルキル基が好ましく、例え
ばベンジル基、フェネチル(フェニルエチル)基、フェ
ニルブチル基、ナフチルメチル基、ナフチルエチル基な
どが挙げられる。The aralkyl group in R1 and R2 has 1 to 1 carbon atoms.
An aralkyl group having 6 alkyl chains is preferable, and examples thereof include a benzyl group, a phenethyl (phenylethyl) group, a phenylbutyl group, a naphthylmethyl group, and a naphthylethyl group.
Y中の低級アルキルカルボニル基の低級アルキル基とし
ては炭素数1〜4の低級アルキル基が好ましく、このよ
うな低級アルキルカルボニル基としては、例えばメチル
カルボニル基、エチルカルボニル基、プロピルカルボニ
ル基、ブチルカルボニル基などが挙げられる。The lower alkyl group in the lower alkylcarbonyl group in Y is preferably a lower alkyl group having 1 to 4 carbon atoms, and examples of such lower alkylcarbonyl groups include methylcarbonyl group, ethylcarbonyl group, propylcarbonyl group, butylcarbonyl group. Examples include groups.
Y中の低級アルコキシ基としては炭素数1〜4の低級ア
ルコキシ基が好ましく、このような低級アルコキシ基と
しては、例えばメトキシ基、エトキシ基などが挙げられ
る。The lower alkoxy group in Y is preferably a lower alkoxy group having 1 to 4 carbon atoms, and examples of such lower alkoxy groups include methoxy and ethoxy groups.
Y中のジ低級アルキルアミノカルボニル基の低級アルキ
ル基としては炭素数1〜4の低級アルキル基が好ましく
、このようなジ低級アルキルアミノカルボニル基として
は、例えばジメチルアミノカルボニル基、ジエチルアミ
ノカルボニル基などが挙げられる。The lower alkyl group of the di-lower alkylaminocarbonyl group in Y is preferably a lower alkyl group having 1 to 4 carbon atoms, and such di-lower alkylaminocarbonyl groups include, for example, dimethylaminocarbonyl group, diethylaminocarbonyl group, etc. Can be mentioned.
Y中のアリール基としては、例えばフェニル基、ナフチ
ル基などが挙げられる。Examples of the aryl group in Y include phenyl group and naphthyl group.
Y中の低級アルコキシカルボニル基の低級アルコキシ基
としては炭素数1〜4の低級アルコキシ基が好ましく、
このような低級アルコキシカルボニル基としては、例え
ばメトキシカルボニル基、エトキシカルボニル基が挙げ
られる。The lower alkoxy group of the lower alkoxycarbonyl group in Y is preferably a lower alkoxy group having 1 to 4 carbon atoms,
Examples of such a lower alkoxycarbonyl group include a methoxycarbonyl group and an ethoxycarbonyl group.
その他、Yはシアノ基、ハロゲン原子、カルボキシル基
、モルホリノカルボニル基またはニトロ基であってもよ
く、ハロゲン原子としては塩素原子、フッ素原子、臭素
原子、ヨウ素原子などが挙げられる。In addition, Y may be a cyano group, a halogen atom, a carboxyl group, a morpholinocarbonyl group, or a nitro group, and examples of the halogen atom include a chlorine atom, a fluorine atom, a bromine atom, an iodine atom, and the like.
一般式[I]の化合物の好ましいものとして以下の化合
物が例示される。The following compounds are exemplified as preferable compounds of general formula [I].
(1)6−ジアツー2,2−ジメチル−4−[(N−シ
アノ−ホルムイミドイル)アミノコ−2H−ベンゾ[b
] ピラン
(R’ =H,R1=H,Y=6−CN)(2)6−ジ
アツー2,2−ジメチル−4−[(N−シアノ−アセト
イミドイル)アミノ] −2Hベンゾ[bコピラン
(Rj =H,R1=Me、 Y=6−CN)(3)6
−ジアツー2,2−ジメチル−4−[(N−シアノ−プ
ロピオンイミドイル)アミノコ2H−ベンゾ[bコピラ
ン
(Rj =H,R2=Et、 Y=6−CN)(4)6
−ジアツー2.2−ジメチル−4−[(N−シアノ−n
−ブチロイミドイル)アミノコ−2H−ベンゾ[bコピ
ラン
(R’ =H,R2=n−Pr、 Y=6−CN)(5
)6−ジアツー2.2−ジメチル−4−[(N−シアノ
−イソブチロイミドイル)アミノコ−2H−ベンゾ[b
] ピラン
(R’ =H,R’ = i s o−’P r、 Y
=6−CN)
(6)6−ジアツー2,2−ジメチル−4−[(N−シ
アノ−n−バレロイミドイル)アミノコ−2H−ベンゾ
[bl ピラン
(R1=H,R2=n−Bu、Y=6−CN:(7)6
−ジアツー2.2−ジメチル−4−[(N−シアノーイ
ソバレロイミドイル)アミノ]=2H−ベンゾ[bl
ピラン
(R” =H,R2=i 5o−Bu、Y=6−CN)
(8)6−ジアツー2,2−ジメチル−4−[(N−シ
アノ−メチルエチルアセトイミドイル)アミノコ−2H
−ベンゾ[bコ ピラン
(R’ =H,R’ =sec−Bu、Y=6−CN)
(9)6−ジアツー2,2−ジメチル−4−[(N−シ
アノーピバロイミドイル)アミノコ−2H−ベンゾ[b
l ピラン
(R’ =H,R2−t e r t−Bu、 Y=
6−CN)
(10) 6−ジアツー2,2−ジメチル−4−[(
N−シアノ−n−ヘキサノイミドイル)アミノコ−2H
−ベンゾ[bl ピラン
(R’ =H,R2=n−ペンチル、y=6−CN)
(ll) 6−ジアツー2,2−ジメチル−4=[(
N−シアノ−n−ヘプタノイミドイル)アミノコ−2H
−ベンゾ[bコ ピラン
(R’ =H,R1! =n−ヘキシル、Y=6−CN
))
(12) 6−ジアツー2.2−ジメチル−4−[(
N−シアノ−2−メトキシアセトイミドイル)アミノ]
−2H−ベンゾ[bl ピラン(R’ =H,RE
=メトキシメチル、Y=6−CN)
(13) 6−ジアツー2,2−ジメチル−4−[(
N−シアノ−3−メトキシプロピオンイミドイル)アミ
ノコ−2H−ベンゾ[bl ピラン(R’ =H,R
2=メトキシエチル、Y=6−CN)
(14) 6−ジアツー2,2−ジメチル−4−[(
N−シアノ−ベンゾイミドイル)アミノコ−2H−ベン
ゾ[bl ピラン
(R1=H,R’ =フェニル、Y=6−CN)(15
) 6−ジアツー2.2−ジメチル−4−[(N−シ
アノ−2〜フエニルアセトイミドイル)アミノコ−2H
−ベンゾ[bl ピラン(R’ =H,R2=ベンジル
、Y=6−CN)(1B) 6−ジアツー2.2−ジ
メチル−4−[(N−シアノ−3−フェニルプロピオン
イミドイル)アミノコ−2H−ベンゾ[bl ピラン(
R1=H,R2=フェネチル、Y=6−CN)
(17) 6−ジアツー2.2−ジメチル−4−[N
−メチル−(N−シアノ−ホルムイミドイル)アミノコ
−2H−ベンゾ[bコピラン
(Rj =Me、 R’ −H,Y=6−CN)(1
8) 6−ジアツー2,2−ジメチル−4−[N−メ
チル−(N−シアノ−アセトイミドイル)アミノコ−2
H−ベンゾ[b]コピラ
ンRj =Me、R’ =Me、Y=6−CN)(19
) 6−ジアツー2.2−ジメチル−4−[N−メチ
ル−(N−シアノ−プロピオンイミドイル)アミノコ−
2H−ベンゾ[bl ピラン(R’ =Me、R2=E
t、Y=6−CN)(20) 6−ジアツー2,2−
ジメチル−4−[N−メチル−(N−シアノ−n−ブチ
ロイミドイル)アミノコ−2H−ベンゾ[bl ピラン
(R’ =Me、R1! =n−Pr、Y=5−CN
)
(2L) 6−ジアツー2,2−ジメチル−4−[N
−メチル−(N−シアノ−ベンゾイミドイノリアミノ]
−2H−ベンゾ[bl ピラン(R’ =Me、RE
=フェニル、Y=6−CN)
(22) 6−ジアツー2.2−ジメチル−4−[N
−エチル−(N−シアノ−ホルムイミドイル)アミノコ
−2H−ベンゾ[bコピラン
<R1−Et、R2=H,Y=6−CN)(23)
6−ジアツー2,2−ジメチル−4−[N−エチル−(
N−シアノ−アセトイミドイル)アミノコ−2H−ベン
ゾ[bl ピラン(Rj =Et、 R2=Me、
Y=6−CN)(24) 6−ジアツー2,2−ジメ
チル−4−[Nエチル−(N−シアノ−プロピオンイミ
ドイル)アミノコ−2H−ベンゾ[bl ピラン(Rj
=Et、R2=Et、Y=6−CN)(25) 6
−ジアツー2.2−ジメチル−4−[N−エチル−(N
−シアノ−ベンゾイミドイル)アミノコ−2H−ベンゾ
[bl ピラン(R’ =Et、R2=フェニル、Y=
6−CN)
(26) 6−ジアツー2.2−ジメチル−4−[N
−n−プロピル−(N−シアノ−ホルムイミドイル)ア
ミノコ−2H−ベンゾ[bl ピラン(R1=n−Pr
、 R2=H,Y=6−CN)(27) 6−ジアツ
ー2.2−ジメチル−4−[N−n−プロピル−(N−
シアノ−アセトイミドイル)アミノコ−2H−ベンゾ[
bl ピラン(R’ =n−Pr、R1=Me、Y=6
−CN)
(28) 6−ジアツー2.2−ジメチル−4−[N
−n−プロピル−(N−シアノ−ベンゾイミドイル)ア
ミノコ−2H−ベンゾ[bl ピラン(R’ =n−P
r、R1=7エ:ル、Y=6−CN)
(29) 6−ジアツー2.2−ジメチル−4−[N
−n−ブチル−(N−シアノ−ホルムイミドイル)アミ
ノコ−2H−ベンゾ[bl ピラン(R’ =n−Bu
、R2=H,Y=6−CN)(30) 6−ジアツー
2,2−ジメチル−4−[N−n−ブチル−(N−シア
ノ−アセトイミドイル)アミノコ−2H−ベンゾ[bl
ピラン(Rj =n−Bu、Rffi =Me、Y=
6−CN)
(31) 6−ジアツー2,2−ジメチル−4−[N
−ベンジル−(N−シアノ−ホルムイミドイル)アミノ
コ−2H−ベンゾ[bコピラン
(R1=ベンジル、R1=H,Y=6−CN)(32)
6−ジアツー2.2−ジメチル−4−[N−ヘンシ
ル−(N−シアノ−アセトイミドイル)アミノコ−2H
−ベンゾ[bコ ピラン(R1=ベンジル、 R2=M
e、 Y=5−CN)
(33) 6−ジアツー2.2−ジメチル−4−[N
−アリル−(N−シアノ−ホルムイミドイル)アミノコ
−2H−ベンゾ[bコピラン
(R1=アリル、R2−H,Y=6−CN)(34)
6−ジアツー2,2−ジメチル−4−[N−アリル−
(N−シアノ−アセトイミドイル)アミノコ−2H−ベ
ンゾ[bコ ピラン(R1=アリル、R2=Me、Y=
6−CN)(35) 6−ジアツー2.2−ジメチル
−4−[N−2−メトキシエチル−(N−シアノ−ホル
ムイミドイル)アミノコ−2H−ベンゾ[bl ピラン
(R1−メトキシエチル、R1−H,Y=6−CN)
(36) 6−ジアツー2,2−ジメチル−4−[N
−2−メトキシエチル−(N−シアノ−アセトイミドイ
ル)アミノ] −2H−ベンゾ[bl ピラン
(R1=メトキシエチル、R2=Me、Y=6− CN
)
(37) 6−ジアツー2.2−ジメチル−4−[N
−プロパルギル−(N−シアノ−ホルムイミドイル)ア
ミノコ−2H−ベンゾ[b]コピランR1=プロパルギ
ル、R2=H,Y=5−CN)
(38)、6−ジアツー2.2−ジメチル−4−[N−
プロパルギル−(N−シアノ−アセトイミドイル)アミ
ノコ−2H−ベンゾ[b]コピランR1=プロパルギル
、 R2=Me、 Y=5−CN)
(39) 6−クロロ−2,2−ジメチル−4−[(
N−シアノ−アセトイミドイル)アミノコ−2H−ベン
ゾ[bl ピラン
(R’−H,R1−Me、Y−6−C1)(40)
6−フルオロ−2,2−ジメチル−4−[(N−シアノ
−アセトイミドイル)アミノコ−2H−ベンゾ[bl
ピラン
(R’ =H,R2=Me、Y=6−F)(41)
6−ニトロ−2,2−ジメチル−4[(N−シアノ−
アセトイミドイル)アミノコ2H−ベンゾ[bl ピラ
ン
(R’ =H,R1=Me、Y=6−NO2)(42)
6−ブロモ−2,2−ジメチル−4−[(N−シア
ノ−アセトイミドイル)アミノコ−2H−ベンゾ[bl
ピラン
(R’ =H,R2=Me、 Y =6−B r)(4
3) 6−ニトロ−2,2−ジメチル−4−[(N−
シアノ−プロピオンイミドイル)アミノコ−2H−ベン
ゾ[bコ ピラン
(R’ =H,R2=E t、Y=6−NO2)(44
) 6−メチル−2,2−ジメチル−4−[(N−シ
アノ−アセトイミドイル)アミノコ−2H−ベンゾ[b
l ピラン
(R’ =H,R1’ =Me、Y=6−CH3)(4
5) 6−メチル−2,2−ジメチル−4[(N−シ
アノ−プロピオンイミドイル)アミノコ−2H−ベンゾ
[bl ピラン
(R1=H,R1! =Et、Y=6−CH3)(46
) 6−ニトロ−2,2−ジメチル−4−[(N−シ
アノ−ホルムイミドイル)アミノコ2H−ベンゾ[bコ
ピラン
(R4=H,R2=H,Y=6−NO2)(47)
6−ニトロ−2,2−ジメチル−4=[(N−シアノ−
n−ブチロイミドイル)アミノコ−2H−ベンゾ[bl
ピラン
(R’ =H,R2=n−Pr、Y=6NO2)
(48) 6−ニトロ−2,2−ジメチル−4−[(
N−シアノ−フェニルアセトイミドイル)アミノコ−2
H−ベンゾ[bl ピラン(R1=H,R2=ベンジル
、 Y=6N02)
(49) 6−ブロモ−2,2−ジメチル−4=[(
N−シアノ−ホルムイミドイル)アミノコ−2H−ベン
ゾ[bl ピラン
(R” =H,R2=H,Y=6−Br)(50)
6−ジアツー2,2−ジメチル−4−[N−エトキシカ
ルボニルメチル−(N−シアノーアセトイミドイル)ア
ミノコ−2H−ベンゾ[bl ピラン
(R1=エトキシカルボニルメチル、R2=Me、Y=
6−CN)
(51) 6−ジアツー2,2−ジメチル−4−[N
−イソプロピル−(N−シアノ−アセトイミドイル)ア
ミノコ−2H−ベンゾ[bl ピラン(R’ =i 5
o−Pr、R2=Me、Y=6−CN)
(52) 6−ジアツー2.2−ジメチル−4−[N
イソブチル−(N−シアノ−アセトイミドイル)アミノ
コ−2H−ベンゾ[bl ピラン(R1= i s o
−Bu、 R2=Me、 Y=6−CN)
(53) 6−ジアツー2.2−ジメチル−4−[N
−フェネチル−(N−シアノ−アセトイミドイル)アミ
ノコ−2H−ベンゾ[bl ピラン(R1=フェネチル
、 R2=Me、 Y=6−CN)
(54) 6−ジアツー2,2−ジメチル−4−[N
(N、N−ジメチルエチル)−(N−シアノ−アセトイ
ミドイル)アミノコ−2H−ベンゾ[bl ピラン
(R1=N、 N−ジメチルエチル、R2=Me、Y
=6−CN)
(55) 6−ジアツー2.2−ジメチル−4−[N
−ヒドロキシエチル−(N−シアノーアセトイミドイル
)アミノコ−2H−ベンゾ[bl ピラン
(R1=ヒドロキシエチル、R2=Me。(1) 6-dia-2,2-dimethyl-4-[(N-cyano-formimidoyl)aminoco-2H-benzo[b
] Pyran (R' = H, R1 = H, Y = 6-CN) (2) 6-dia2-2,2-dimethyl-4-[(N-cyano-acetimidoyl)amino] -2H benzo[b copyran (Rj = H, R1 = Me, Y = 6-CN) (3) 6
-dia2-2,2-dimethyl-4-[(N-cyano-propionimidoyl)aminoco2H-benzo[b copyran (Rj = H, R2 = Et, Y = 6-CN) (4) 6
-dia2-2,2-dimethyl-4-[(N-cyano-n
-butyroimidoyl)aminoco-2H-benzo[b copyran (R' = H, R2 = n-Pr, Y = 6-CN) (5
)6-dia2-2,2-dimethyl-4-[(N-cyano-isobutyrimidoyl)aminoco-2H-benzo[b
] Pyran (R' = H, R' = iso-'P r, Y
=6-CN) (6) 6-Dia-2,2-dimethyl-4-[(N-cyano-n-valeroimidoyl)aminoco-2H-benzo[bl pyran (R1=H, R2=n-Bu, Y= 6-CN: (7)6
-dia2-2,2-dimethyl-4-[(N-cyanoisovaleroimidoyl)amino]=2H-benzo[bl
Pyran (R" = H, R2 = i 5o-Bu, Y = 6-CN) (8) 6-dia2-2,2-dimethyl-4-[(N-cyano-methylethylacetimidoyl)aminoco-2H
-benzo[bcopyran (R' = H, R' = sec-Bu, Y = 6-CN) (9) 6-dia2-2,2-dimethyl-4-[(N-cyanopivalimidoyl) Aminoco-2H-benzo[b
l pyran (R'=H, R2-tert-Bu, Y=
6-CN) (10) 6-dia-2,2-dimethyl-4-[(
N-cyano-n-hexanoimidoyl)aminoco-2H
-benzo[bl pyran (R' = H, R2 = n-pentyl, y = 6-CN) (ll) 6-dia2-2,2-dimethyl-4 = [(
N-cyano-n-heptanoimidoyl)aminoco-2H
-benzo[bcopyran (R' = H, R1! = n-hexyl, Y = 6-CN
)) (12) 6-Dia-2,2-dimethyl-4-[(
N-cyano-2-methoxyacetimidoyl)amino]
-2H-benzo[bl pyran (R' = H, RE
=methoxymethyl, Y=6-CN) (13) 6-dia-2,2-dimethyl-4-[(
N-cyano-3-methoxypropionimidoyl)aminoco-2H-benzo[bl pyran (R' = H, R
2=methoxyethyl, Y=6-CN) (14) 6-diatwo-2,2-dimethyl-4-[(
N-cyano-benzimidoyl)aminoco-2H-benzo[bl pyran (R1=H, R'=phenyl, Y=6-CN) (15
) 6-dia2,2-dimethyl-4-[(N-cyano-2-phenylacetimidoyl)aminoco-2H
-benzo[bl pyran (R' = H, R2 = benzyl, Y = 6-CN) (1B) 6-dia2-2,2-dimethyl-4-[(N-cyano-3-phenylpropionimidoyl)aminoco- 2H-benzo[bl pyran(
R1=H, R2=phenethyl, Y=6-CN) (17) 6-diatwo-2,2-dimethyl-4-[N
-Methyl-(N-cyano-formimidoyl)aminoco-2H-benzo[b copyran (Rj = Me, R' -H, Y = 6-CN) (1
8) 6-dia2-2,2-dimethyl-4-[N-methyl-(N-cyano-acetimidoyl)aminoco-2
H-benzo[b]copyran Rj = Me, R' = Me, Y = 6-CN) (19
) 6-Dia-2,2-dimethyl-4-[N-methyl-(N-cyano-propionimidoyl)aminoco-
2H-benzo[bl pyran (R' = Me, R2 = E
t, Y=6-CN) (20) 6-dia2,2-
Dimethyl-4-[N-methyl-(N-cyano-n-butyromidoyl)aminoco-2H-benzo[bl pyran (R' = Me, R1! = n-Pr, Y = 5-CN
) (2L) 6-dia-2,2-dimethyl-4-[N
-Methyl-(N-cyano-benzimidinolyamino)
-2H-benzo[bl pyran (R' = Me, RE
= phenyl, Y = 6-CN) (22) 6-diatwo-2,2-dimethyl-4-[N
-Ethyl-(N-cyano-formimidoyl)aminoco-2H-benzo[bcopyran<R1-Et, R2=H, Y=6-CN) (23)
6-Dia-2,2-dimethyl-4-[N-ethyl-(
N-cyano-acetimidoyl)aminoco-2H-benzo[bl pyran (Rj = Et, R2 = Me,
Y=6-CN) (24) 6-diatu2,2-dimethyl-4-[Nethyl-(N-cyano-propionimidoyl)aminoco-2H-benzo[bl pyran(Rj
=Et, R2=Et, Y=6-CN) (25) 6
-dia2-2,2-dimethyl-4-[N-ethyl-(N
-cyano-benzimidoyl)aminoco-2H-benzo[bl pyran (R' = Et, R2 = phenyl, Y =
6-CN) (26) 6-dia-2,2-dimethyl-4-[N
-n-propyl-(N-cyano-formimidoyl)aminoco-2H-benzo[bl pyran (R1=n-Pr
, R2=H, Y=6-CN) (27) 6-dia-2,2-dimethyl-4-[N-n-propyl-(N-
cyano-acetimidoyl)aminoco-2H-benzo[
bl pyran (R' = n-Pr, R1 = Me, Y = 6
-CN) (28) 6-dia2-2,2-dimethyl-4-[N
-n-propyl-(N-cyano-benzimidoyl)aminoco-2H-benzo[bl pyran (R' = n-P
r, R1=7E:R, Y=6-CN) (29) 6-dia2-2,2-dimethyl-4-[N
-n-butyl-(N-cyano-formimidoyl)aminoco-2H-benzo[bl pyran (R' = n-Bu
, R2=H, Y=6-CN) (30) 6-dia-2,2-dimethyl-4-[N-n-butyl-(N-cyano-acetimidoyl)aminoco-2H-benzo[bl
Pyran (Rj = n-Bu, Rffi = Me, Y =
6-CN) (31) 6-dia-2,2-dimethyl-4-[N
-benzyl-(N-cyano-formimidoyl)aminoco-2H-benzo[b-copyran (R1=benzyl, R1=H, Y=6-CN) (32)
6-Diatu2,2-dimethyl-4-[N-hensyl-(N-cyano-acetimidoyl)aminoco-2H
-benzo[bcopyran (R1=benzyl, R2=M
e, Y=5-CN) (33) 6-diatwo-2,2-dimethyl-4-[N
-Allyl-(N-cyano-formimidoyl)aminoco-2H-benzo[b-copyran (R1=allyl, R2-H, Y=6-CN) (34)
6-dia2-2,2-dimethyl-4-[N-allyl-
(N-cyano-acetimidoyl)aminoco-2H-benzo[bcopyran (R1=allyl, R2=Me, Y=
6-CN) (35) 6-Diatu2.2-dimethyl-4-[N-2-methoxyethyl-(N-cyano-formimidoyl)aminoco-2H-benzo[bl pyran(R1-methoxyethyl, R1 -H, Y=6-CN) (36) 6-dia2-2,2-dimethyl-4-[N
-2-methoxyethyl-(N-cyano-acetimidoyl)amino] -2H-benzo[bl pyran (R1=methoxyethyl, R2=Me, Y=6- CN
) (37) 6-dia2-2,2-dimethyl-4-[N
-propargyl-(N-cyano-formimidoyl)aminoco-2H-benzo[b]copyran R1=propargyl, R2=H, Y=5-CN) (38), 6-diatu-2,2-dimethyl-4- [N-
Propargyl-(N-cyano-acetimidoyl)aminoco-2H-benzo[b]copyran R1=propargyl, R2=Me, Y=5-CN) (39) 6-chloro-2,2-dimethyl-4-[ (
N-cyano-acetimidoyl)aminoco-2H-benzo[bl pyran(R'-H, R1-Me, Y-6-C1) (40)
6-fluoro-2,2-dimethyl-4-[(N-cyano-acetimidoyl)aminoco-2H-benzo[bl
Pyran (R' = H, R2 = Me, Y = 6-F) (41)
6-nitro-2,2-dimethyl-4[(N-cyano-
acetimidoyl)aminoco2H-benzo[bl pyran (R' = H, R1 = Me, Y = 6-NO2) (42)
6-bromo-2,2-dimethyl-4-[(N-cyano-acetimidoyl)aminoco-2H-benzo[bl
Pyran (R' = H, R2 = Me, Y = 6-Br) (4
3) 6-nitro-2,2-dimethyl-4-[(N-
Cyano-propionimidoyl)aminoco-2H-benzo[bcopyran (R' = H, R2 = E t, Y = 6-NO2) (44
) 6-Methyl-2,2-dimethyl-4-[(N-cyano-acetimidoyl)aminoco-2H-benzo[b
l Pyran (R' = H, R1' = Me, Y = 6-CH3) (4
5) 6-Methyl-2,2-dimethyl-4[(N-cyano-propionimidoyl)aminoco-2H-benzo[bl pyran (R1=H,R1!=Et, Y=6-CH3) (46
) 6-nitro-2,2-dimethyl-4-[(N-cyano-formimidoyl)aminoco2H-benzo[b copyran (R4=H, R2=H, Y=6-NO2) (47)
6-nitro-2,2-dimethyl-4=[(N-cyano-
n-butyromidoyl)aminoco-2H-benzo[bl
Pyran (R' = H, R2 = n-Pr, Y = 6NO2) (48) 6-nitro-2,2-dimethyl-4-[(
N-cyano-phenylacetimidoyl)aminoco-2
H-benzo[bl pyran (R1=H, R2=benzyl, Y=6N02) (49) 6-bromo-2,2-dimethyl-4=[(
N-cyano-formimidoyl)aminoco-2H-benzo[bl pyran (R”=H, R2=H, Y=6-Br) (50)
6-dia2-2,2-dimethyl-4-[N-ethoxycarbonylmethyl-(N-cyanoacetimidoyl)aminoco-2H-benzo[bl pyran (R1=ethoxycarbonylmethyl, R2=Me, Y=
6-CN) (51) 6-dia-2,2-dimethyl-4-[N
-isopropyl-(N-cyano-acetimidoyl)aminoco-2H-benzo[bl pyran (R' = i 5
o-Pr, R2=Me, Y=6-CN) (52) 6-diatwo-2,2-dimethyl-4-[N
Isobutyl-(N-cyano-acetimidoyl)aminoco-2H-benzo[bl pyran (R1= iso
-Bu, R2=Me, Y=6-CN) (53) 6-dia-2,2-dimethyl-4-[N
-Phenethyl-(N-cyano-acetimidoyl)aminoco-2H-benzo[bl pyran (R1=phenethyl, R2=Me, Y=6-CN) (54) 6-diatu-2,2-dimethyl-4-[ N
(N,N-dimethylethyl)-(N-cyano-acetimidoyl)aminoco-2H-benzo[bl pyran (R1=N, N-dimethylethyl, R2=Me, Y
=6-CN) (55) 6-dia2-2,2-dimethyl-4-[N
-Hydroxyethyl-(N-cyanoacetimidoyl)aminoco-2H-benzo[bl pyran (R1=hydroxyethyl, R2=Me.
Y=6−CN)
(56) 6−ニトロ−2,2−ジメチル−4−[N
−メチル−(N−シアノ−アセトイミドイル)アミノコ
−2H−ベンゾ[bl ピラン(R’ =Me、R2=
Me、Y=6−NO2)(57) 6−ニトロ−2,
2−ジメチル−4−[N−アリル−(N−シアノ−アセ
トイミドイル)アミノコ−2H−ベンゾ[bl ピラン
(R1−アリル、R2=Me、Y=6
NO2)
(5g) 6−ニトロ−2,2−ジメチル−4−[N
−プロパルギル−(N−シアノ−アセトイミドイル)ア
ミノコ−2H−ベンゾ[bコピラン(R1=プロパルギ
ル、R’ =Me、Y=6−NO2)
(59) 6−、ニトロ−2,2−ジメチル−4−[
N−メトキシカルボニルメチル−(N−シアノ−アセト
イミドイル)アミノ] −2H−ベンゾ[bl ピラン
(R1=メトキシカルボニルメチル Bt ==Me、
Y=6−N(h )
(Go) 6−ニトロ−2,2−ジメチル−4−[N
−メチル−(N−シアノ−ホルムイミドイル)アミノコ
−2H−ベンゾ[bl ピラン(R1=Me、 RE
=H,Y=6−Nov )(61) 6−ニトロ−2
,2−ジメチル−4−[N−ヒドロキシエチル−(N−
シアノ−アセトイミドイル)アミノコ−2H−ベンゾ[
bl ピラン
(R1=ヒドロキシエチル、 R1! =Me。Y=6-CN) (56) 6-nitro-2,2-dimethyl-4-[N
-Methyl-(N-cyano-acetimidoyl)aminoco-2H-benzo[bl pyran (R'=Me, R2=
Me, Y=6-NO2) (57) 6-nitro-2,
2-dimethyl-4-[N-allyl-(N-cyano-acetimidoyl)aminoco-2H-benzo[bl pyran (R1-allyl, R2=Me, Y=6 NO2) (5g) 6-nitro-2 ,2-dimethyl-4-[N
-propargyl-(N-cyano-acetimidoyl)aminoco-2H-benzo[b copyran (R1 = propargyl, R' = Me, Y = 6-NO2) (59) 6-, nitro-2,2-dimethyl- 4-[
N-methoxycarbonylmethyl-(N-cyano-acetimidoyl)amino]-2H-benzo[bl pyran (R1=methoxycarbonylmethyl Bt==Me,
Y=6-N(h) (Go) 6-nitro-2,2-dimethyl-4-[N
-Methyl-(N-cyano-formimidoyl)aminoco-2H-benzo[bl pyran (R1=Me, RE
=H, Y=6-Nov ) (61) 6-nitro-2
,2-dimethyl-4-[N-hydroxyethyl-(N-
cyano-acetimidoyl)aminoco-2H-benzo[
bl pyran (R1=hydroxyethyl, R1!=Me.
Y−6−Not)
(62) 6−ニトロ−2,2−ジメチル−4−[N
−エチル−(N−シアノ−アセトイミドイル)アミノコ
−2H−ベンゾ[bl ピラン(R1=Et、R’ =
M、e、Y=6 NO2)(63) 6−ニトロ−
2,2−ジメチル−4−[N−メチル−(N−シアノ−
プロピオンイミドイル)アミノコ−2H−ベンゾ[bl
ピラン(R1=Me、R″! =E t、 Y=6−
NO2)(84) 6−ブロモ−2,2−ジメチル−
4−[N−メチル−(N−シアノ−アセトイミドイル)
アミノコ−2H−ベンゾ[bl ピラン(R’ =Me
、RE =Me、Y=6−Br)(65) 6−ジア
ツー2.2−ジメチル−4−[N−アセチル−(N−シ
アノ−アセトイミドイル)アミノコ−2H−ベンゾ[b
l ピラン(R1=アセチル、R1=Me、Y=6−C
N)
(6B) 6−ジアツー2.2−ジメチル−4−[N
−プロピルカルボニル−(N−シアノ−アセトイミドイ
ル)アミノ] −2H−ベンゾ[bl ピラン
(R1;プロピルカルボニル、 R2=Me。Y-6-Not) (62) 6-nitro-2,2-dimethyl-4-[N
-ethyl-(N-cyano-acetimidoyl)aminoco-2H-benzo[bl pyran (R1=Et, R'=
M, e, Y=6 NO2) (63) 6-nitro-
2,2-dimethyl-4-[N-methyl-(N-cyano-
propionimidoyl)aminoco-2H-benzo[bl
Pyran (R1=Me, R''!=E t, Y=6-
NO2) (84) 6-bromo-2,2-dimethyl-
4-[N-methyl-(N-cyano-acetimidoyl)
Aminoco-2H-benzo[bl pyran (R' = Me
, RE = Me, Y = 6-Br) (65) 6-dia2-2,2-dimethyl-4-[N-acetyl-(N-cyano-acetimidoyl)aminoco-2H-benzo[b
l Pyran (R1=acetyl, R1=Me, Y=6-C
N) (6B) 6-dia2-2,2-dimethyl-4-[N
-propylcarbonyl-(N-cyano-acetimidoyl)amino] -2H-benzo[bl pyran (R1; propylcarbonyl, R2=Me.
Y−6−CN)
(67) 6−ジアツー2,2−ジメチル−4−[N
−フェニルビニルカルボニル−(N−シアノ−アセトイ
ミドイル)アミノ] −2H−ベンゾ[bl ピラン
(R1=フェニルビニルカルボニル、R2=Me、Y=
6−CN)
(6g) 6−ジアツー2.2−ジメチル−4−[N
−フェニルカルボニル−(N−シアノ−アセトイミドイ
ル)アミノコ−2H−ベンゾ[bl ピラン
(R1冨フェニルカルボニル、R1=Me。Y-6-CN) (67) 6-dia2-2,2-dimethyl-4-[N
-phenylvinylcarbonyl-(N-cyano-acetimidoyl)amino] -2H-benzo[bl pyran (R1=phenylvinylcarbonyl, R2=Me, Y=
6-CN) (6g) 6-dia2-2,2-dimethyl-4-[N
-Phenylcarbonyl-(N-cyano-acetimidoyl)aminoco-2H-benzo[bl pyran (R1 phenylcarbonyl, R1=Me.
Y−6−CN)
(69) 6−ジアツー2,2−ジメチル−4−[N
−エトキシカルボニル−(N−シアノ−アセトイミドイ
ル)アミノコ−2H−ベンゾ[bl ピラン
(R1=エトキシカルボニル、 R1’ =M、e。Y-6-CN) (69) 6-dia2-2,2-dimethyl-4-[N
-ethoxycarbonyl-(N-cyano-acetimidoyl)aminoco-2H-benzo[bl pyran (R1 = ethoxycarbonyl, R1' = M, e.
Y=6−CN)
(70) 6−ニトロ−2,2−ジメチル−4−[N
アセチル−(N−シアノ−アセトイミドイル)アミノ3
−2H−ベンゾ[bl ピラン(R1=アセチル、 R
e =Me、 Y=6−NO2)
(71) 6−二トロー2.2−ジメチル−4−[N
−フェニルカルボニル−(N−シアノ−アセトイミドイ
ル)アミノコ−2H−ベンゾ[bl ピラン
(R1=フェニルカルボニル、 R2=Me。Y=6-CN) (70) 6-nitro-2,2-dimethyl-4-[N
Acetyl-(N-cyano-acetimidoyl)amino 3
-2H-benzo[bl pyran (R1=acetyl, R
e = Me, Y = 6-NO2) (71) 6-nitro2.2-dimethyl-4-[N
-phenylcarbonyl-(N-cyano-acetimidoyl)aminoco-2H-benzo[bl pyran (R1=phenylcarbonyl, R2=Me.
Y=6−NOp)
(72) 6−カルボキシ−2,2−ジメチル−4−
[(N−シアノ−アセトイミドイル)アミノコ−2H−
ベンゾ[bl ピラン
(R’ =H,R1=Me、Y=6−カルボキシル)
(73) 6− (4−モルホリノ)カルボニル−2
゜2−ジメチル−4−[(N−シアノ−アセトイミドイ
ル)アミノコ−2H−ベンゾ[b] ピラン
(R” =H,R2=Me、 Y=6− (4−モルホ
リノ)カルボニル)
(74)6−(ジエチルアミノ)カルボニル−2゜2−
ジメチル−4−[(N−シアノ−アセトイミドイル)ア
ミノコ−2H−ベンゾ[b] ピラン
(R+ =H,R2=Me、Y=6− (ジエチルアミ
ノ)カルボニル)
(75) 6−メドキシカルボニルー2,2−ジメチ
ル−4−[(N−シアノ−アセトイミドイル)アミノコ
−2H−ベンゾ[b] ピラン(R’ =H,R’ =
Me、Y=6−メドキシカルボニル)
前記一般式[I]で示される化合物は必要に応じて医薬
上許容される塩にすることができ、このような塩として
は、アルカリ金属塩(例えば、ナトリウム塩、カリウム
塩、セシウム塩など)、アルカリ土類金属塩(例えは、
カルシウム塩、マグネシウム塩など)、アンモニウム塩
のような無機塩基との塩、有機アミン塩(例えば、トリ
エチルアミン塩、ピリジン塩、ピコリン塩、エタノール
アミン塩、トリエタノールアミン塩、ジシクロヘキシル
アミン塩、N、 N−ジベンジルエチレンジアミン塩
など)のような有機塩基との塩、無機酸付加塩(例えば
、塩酸塩、臭化水素酸塩、硝酸塩、燐酸塩など)、有機
カルボン酸付加塩または有機スルホン酸付加塩(例えば
、ギ酸塩、酢酸塩、トリフルオロ酢酸塩、マレイン酸塩
、酒石酸塩、メタンスルホン酸塩、ベンゼンスルホン酸
塩、p−トルエンスルホン酸塩など)、塩基性アミノ酸
または酸性アミノ酸(例えば、アルギニン、アスパラギ
ン酸、グルタミン酸など)との塩などが挙げられる。Y=6-NOp) (72) 6-carboxy-2,2-dimethyl-4-
[(N-cyano-acetimidoyl)aminoco-2H-
Benzo[bl pyran (R' = H, R1 = Me, Y = 6-carboxyl) (73) 6- (4-morpholino)carbonyl-2
゜2-dimethyl-4-[(N-cyano-acetimidoyl)aminoco-2H-benzo[b]pyran (R”=H, R2=Me, Y=6-(4-morpholino)carbonyl) (74) 6-(diethylamino)carbonyl-2゜2-
Dimethyl-4-[(N-cyano-acetimidoyl)aminoco-2H-benzo[b]pyran (R+ = H, R2 = Me, Y = 6- (diethylamino)carbonyl) (75) 6-medoxycarbonyl 2,2-dimethyl-4-[(N-cyano-acetimidoyl)aminoco-2H-benzo[b]pyran (R' = H, R' =
Me, Y = 6-medoxycarbonyl) The compound represented by the general formula [I] can be converted into a pharmaceutically acceptable salt if necessary, and such salts include alkali metal salts (e.g. sodium salts, potassium salts, cesium salts, etc.), alkaline earth metal salts (for example,
salts with inorganic bases such as ammonium salts, organic amine salts (e.g. triethylamine salts, pyridine salts, picoline salts, ethanolamine salts, triethanolamine salts, dicyclohexylamine salts, N, N - salts with organic bases such as dibenzylethylenediamine salts, inorganic acid addition salts (e.g. hydrochlorides, hydrobromides, nitrates, phosphates, etc.), organic carboxylic acid addition salts or organic sulfonic acid addition salts. (e.g. formate, acetate, trifluoroacetate, maleate, tartrate, methanesulfonate, benzenesulfonate, p-toluenesulfonate, etc.), basic or acidic amino acids (e.g. arginine , aspartic acid, glutamic acid, etc.).
また、前記一般式[I]で示される化合物は、その多く
の場合、分子内に不斉炭素が存在するが、本発明のベン
ゾピラン誘導体はこれら光学異性体またはそれらの混合
物を包含するものである。Further, in most of the compounds represented by the general formula [I], an asymmetric carbon exists in the molecule, and the benzopyran derivative of the present invention includes these optical isomers or a mixture thereof. .
一般式[I]で示される本発明のベンゾピラン誘導体は
、一般式[II]
2
C=N−CN
[式中、R+ 、R2およびYは一般式[Iコに同じ。The benzopyran derivative of the present invention represented by the general formula [I] has the general formula [II] 2C=N-CN [wherein R+, R2 and Y are the same as the general formula [I].
但し、R1において基R3−Co−を除く。]
で示される化合物を脱水処理することにより得ることが
できる。ここに一般式[I[]中のR1R2およびYの
好ましい具体例は一般式[I]において説明した通りで
ある。However, in R1, the group R3-Co- is excluded. ] It can be obtained by dehydrating the compound shown below. Preferred specific examples of R1R2 and Y in the general formula [I] are as explained in the general formula [I].
この脱水処理は、例えば下記のような2段階法または1
段階法によって実施される。This dehydration treatment can be carried out, for example, by a two-step method or a one-step method as described below.
It is carried out in stages.
2段階法(以下、製法1という) この2段階法を反応式で示すと以下の通りである。Two-step method (hereinafter referred to as manufacturing method 1) The reaction formula for this two-step method is as follows.
R1−C−N−CN
目】
すなわち、一般式[II]の化合物に、R4502Xを
反応させる第1段階の反応は、ピリジン、キノリン、ト
リエチルアミンなどの溶媒中て、好ましくは一10〜+
50℃、特に好ましくは一5〜+10℃の温度で、好ま
しくは30分〜12時間、特に好ましくは1〜6時間行
なわれる。反応試剤であるR’ 5otXとしては、メ
タンスルホニルクロライド、メタンスルホニルブロマイ
ド、p−トルエンスルホニルクロライド、p−)ルエン
スルホニルブロマイドなどが挙げられる。R1-C-N-CN] That is, the first step reaction in which the compound of general formula [II] is reacted with R4502X is preferably carried out in a solvent such as pyridine, quinoline, triethylamine, etc.
It is carried out at a temperature of 50 DEG C., particularly preferably from -5 to +10 DEG C., preferably for 30 minutes to 12 hours, particularly preferably for 1 to 6 hours. Examples of the reaction reagent R' 5otX include methanesulfonyl chloride, methanesulfonyl bromide, p-toluenesulfonyl chloride, p-)toluenesulfonyl bromide, and the like.
第1段階の反応で得られた一般式[III]の化合物を
塩基で処理して目的とする一般式[I]の化合物を得る
第2段階の反応は、ジメチルホルムアミド、ジメチルス
ルホキシド、アセトニトリル、ベンゼン、トルエンなど
の溶媒中で、好ましくは0〜100℃、特に好ましくは
20〜40℃の温度で、好ましくは30分〜24時間、
特に好ましくは3〜12時間行なわれる。塩基としては
、例えば、カリウム tert−ブチラード、カリウム
エチラート、カリウム メチラート、ナトリウム エ
チラート、ナトリウム メチラートなどの金属アルコキ
シドや、1.8−ジアザビシクロ[5,4,01−7−
ウンデセンなどの有機塩基が挙げられる。In the second step, the compound of general formula [III] obtained in the first step reaction is treated with a base to obtain the target compound of general formula [I]. Dimethylformamide, dimethyl sulfoxide, acetonitrile, benzene, , in a solvent such as toluene, preferably at a temperature of 0 to 100°C, particularly preferably 20 to 40°C, preferably for 30 minutes to 24 hours,
Particularly preferably, it is carried out for 3 to 12 hours. Examples of the base include metal alkoxides such as potassium tert-butylate, potassium ethylate, potassium methylate, sodium ethylate, and sodium methylate, and 1,8-diazabicyclo[5,4,01-7-
Examples include organic bases such as undecene.
1段階法 1段階法としては、以下に示すものが挙げられる。one step method Examples of the one-step method include those shown below.
(a)一般式[1]の化合物をテ小うヒド口フランなど
の溶媒中で水素化ナトリウム(N a H)を作用させ
て脱水処理し、一般式[I]の化合物を得る(以下、製
法2という)。(a) The compound of the general formula [1] is dehydrated by the action of sodium hydride (N a H) in a solvent such as trifluoride to obtain the compound of the general formula [I] (hereinafter, (referred to as manufacturing method 2).
(b)一般式[II]の化合物をベンゼンなどの溶媒中
でp−1ルエンスルホン酸を作用させて脱水処理し、一
般式[I]の化合物を得る(以下、製法3という)。(b) The compound of general formula [II] is dehydrated by the action of p-1 toluenesulfonic acid in a solvent such as benzene to obtain the compound of general formula [I] (hereinafter referred to as production method 3).
(C)一般式[II]の化合物をエチルアコールなどの
溶媒中で塩酸を作用させて脱水処理し、数式[I]の化
合物を得る(以下、製法4という)。(C) The compound of formula [II] is dehydrated by the action of hydrochloric acid in a solvent such as ethyl alcohol to obtain the compound of formula [I] (hereinafter referred to as production method 4).
前記一般式[I]の化合物は、上述した2段階法および
1段階法により前記一般式[n]の化合物を脱水処理し
て得る方法の他、R1またはYの置換基の種類に応じて
、例えば以下の方法により得ることもできる。The compound of the general formula [I] can be obtained by dehydrating the compound of the general formula [n] by the above-mentioned two-step method or one-step method, or depending on the type of substituent of R1 or Y, For example, it can also be obtained by the following method.
■−一般式I]においてR1が低級アルキル基、低級ア
ルケニル基、低級アルキニル基、ヒドロキシ低級アルキ
ル基、低級アルコキシ低級アルキル基、低級アルコキシ
カルボニル低級アルキル基、またはアラルキル基である
化合物の製法(以下、製法5という)
一般式[IV]
2
−C=N−CN
(式中、R2およびYは一般式[I]に同じ。)
で示される化合物を、アセトニトリル、メタノール、ベ
ンゼン、DMFなどの有機溶媒中、炭酸カリウム、炭酸
ナトリウム、トリエチルアミン、ナトリウム メチラー
トなどの塩基性化合物の存在下で、一般式[V]
R5−X [V]
(式中、R5は低級アルキル基、低級アルケニル基、低
級アルキニル基、ヒドロキシ低級アルキル基、低級アル
コキシ低級アルキル基、低級アルコキシカルボニル低級
アルキル基、またはアラルキル基を意味し、Xはハロゲ
ン原子を意味する。)
で示される化合物と反応させることにより、前記一般式
[I]においてR1が低級アルキル基、低級アルケニル
基、低級アルキニル基、ヒドロキシ低級アルキル基、低
級アルコキシ低級アルキル基、低級アルコキシカルボニ
ル低級アルキル基、またはアラルキル基である化合物を
得る。(2) A method for producing a compound in which R1 is a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a hydroxy lower alkyl group, a lower alkoxy lower alkyl group, a lower alkoxycarbonyl lower alkyl group, or an aralkyl group in [General Formula I] (hereinafter, Production method 5) A compound represented by the general formula [IV] 2 -C=N-CN (wherein, R2 and Y are the same as in the general formula [I]) is dissolved in an organic solvent such as acetonitrile, methanol, benzene, or DMF. In the presence of a basic compound such as potassium carbonate, sodium carbonate, triethylamine, sodium methylate, etc., the general formula [V] R5-X [V] (wherein, R5 is a lower alkyl group, a lower alkenyl group, a lower alkynyl group) , hydroxy lower alkyl group, lower alkoxy lower alkyl group, lower alkoxycarbonyl lower alkyl group, or aralkyl group, and X means a halogen atom). ] to obtain a compound in which R1 is a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a hydroxy lower alkyl group, a lower alkoxy lower alkyl group, a lower alkoxycarbonyl lower alkyl group, or an aralkyl group.
■−一般式I]においてR1が基R3−CO−である化
合物の製法(以下、製法6という)前記一般式[TV]
で示される化合物を、ピリジン、トリエチルアミンなど
の有機溶媒中で、一般式[■コ
R3−Co−X [VI]
(式中、R3は一般式[I]に同じで、Xはハロゲン原
子を意味する。)
で示される化合物と反応させることにより、前記一般式
[IコにおいてR1が基R3−C0−である化合物を得
る。-Production method of a compound in which R1 is a group R3-CO- in general formula I] (hereinafter referred to as production method 6) The above general formula [TV]
A compound represented by the general formula [■CoR3-Co-X [VI] (wherein, R3 is the same as the general formula [I], and ) By reacting with a compound represented by the formula [I], a compound in which R1 is a group R3-C0- is obtained.
■−一般式I]においてYがカルボキシル基である化合
物の製法(以下、製法7という)一般式[■]
2
−C=N−CN
(式中、R1およびR2は一般式[I]に同じで、R6
はC1−6の低級アルキル基を意味する。)
で示される化合物を加水分解することにより、前記一般
式[I]においてYがカルボキシル基である化合物を得
る。■-General formula I] A method for producing a compound in which Y is a carboxyl group (hereinafter referred to as manufacturing method 7) General formula [■] 2 -C=N-CN (wherein, R1 and R2 are the same as in general formula [I] So, R6
means a C1-6 lower alkyl group. ) A compound in which Y is a carboxyl group in the general formula [I] is obtained by hydrolyzing the compound represented by the formula [I].
■一般式[I]においてYがモルホリノカルボニル基ま
たはジ低級アルキルアミノカルボニル基である化合物の
製法(以下、製法8という)上記製法7により前記一般
式[I]においてYがカルボキシル基である化合物を得
、この化合物を、シンクロヘキシルカルボジイミドなど
の存在下で、モルホリンまたはジアルキルアミンと反応
させることにより、前記一般式[1]においてYがモル
ホリノカルボニル基またはジ低級アルキルアミノカルボ
ニル基である化合物を得る。■Production of a compound in which Y is a morpholinocarbonyl group or di-lower alkylaminocarbonyl group in the general formula [I] (hereinafter referred to as production method 8) A compound in which Y in the general formula [I] is a carboxyl group is prepared by the above production method 7. By reacting this compound with morpholine or dialkylamine in the presence of synchhexylcarbodiimide or the like, a compound of the general formula [1] in which Y is a morpholinocarbonyl group or a di-lower alkylaminocarbonyl group is obtained.
■一般式[I]においてYが低級アルコキシカルボニル
基である化合物の別製法(以下、製法つという)
前記製法7により前記一般式[1]においてYがカルボ
キシル基である化合物を得、この化合物と低級アルコー
ルとを反応させて、前記−般式[I]においてYが低級
アルコキシカルボニル基である化合物を得る。■Another production method for a compound in which Y is a lower alkoxycarbonyl group in the general formula [I] (hereinafter referred to as production method 1) A compound in which Y is a carboxyl group in the general formula [1] is obtained by the above production method 7, and this compound and By reacting with a lower alcohol, a compound represented by the general formula [I] in which Y is a lower alkoxycarbonyl group is obtained.
このようにして得られる一般式[I]の化合物は、必要
に応じて、アルカリ金属の水酸化物、アルカリ土類金属
の水酸化物、無機塩基、有機アミン、有機塩基、無機酸
、有機カルボン酸、有機スルホン酸、塩基性アミノ酸、
酸性アミノ酸等と反応させることにより、前述したよう
な医薬上許容される塩にすることができる。The compound of the general formula [I] obtained in this manner may optionally be an alkali metal hydroxide, an alkaline earth metal hydroxide, an inorganic base, an organic amine, an organic base, an inorganic acid, an organic carboxylic acid, or an organic carboxylic acid. acids, organic sulfonic acids, basic amino acids,
By reacting with an acidic amino acid or the like, it can be made into a pharmaceutically acceptable salt as described above.
本発明のベンゾピラン誘導体は優れたカリウムチャンネ
ル活性化作用を有し、各種平滑筋の弛緩および平滑筋細
胞膜のカリウム透過性を高める。The benzopyran derivative of the present invention has an excellent potassium channel activating effect, and increases relaxation of various smooth muscles and potassium permeability of smooth muscle cell membranes.
本作用を応用した疾患治療の対象としては、高血圧症、
一過性脳虚血発作、脳梗塞、脳動脈硬化症、狭心症、慢
性心不全、心筋梗塞、不整脈などの予防治療に、さらに
は気管、胃腸管、子宮などの平滑筋も弛緩させることか
ら、喘息および呼吸器系の閉塞性疾患や胃腸系疾患、子
宮疾患の治療に利用される。さらに間欠性波性症の治療
にも利用される。Diseases that can be treated using this effect include hypertension,
It is useful for the preventive treatment of transient ischemic attacks, cerebral infarction, cerebral arteriosclerosis, angina pectoris, chronic heart failure, myocardial infarction, arrhythmia, etc. It also relaxes the smooth muscles of the trachea, gastrointestinal tract, uterus, etc. It is used to treat asthma and obstructive diseases of the respiratory system, gastrointestinal system diseases, and uterine diseases. It is also used to treat intermittent wave syndrome.
またカリウムチャンネル活性化作用に基づき血管拡張を
起すことから、発毛促進剤としての利用も考えられる。Furthermore, since it causes vasodilation due to its potassium channel activating effect, it may also be used as a hair growth promoter.
本発明の医薬組成物は、一般式[I]のベンゾピラン誘
導体のみによって構成してもよいが、通常は適当な坦体
と共に製剤にして、経口投与することが好ましい。しか
しながら、他の投与方法、例えば心臓障害を患っている
患者に対しては非経口投与してもよい。経口投与用の製
剤としては、錠剤、カプセル剤、顆粒剤、液剤、懸濁剤
なとがある。これらの製剤は、通常の方法によって容易
に調製することができる。The pharmaceutical composition of the present invention may be composed solely of the benzopyran derivative of general formula [I], but it is usually preferable to formulate it with a suitable carrier and administer it orally. However, other methods of administration may be used, such as parenteral administration for patients suffering from cardiac disorders. Preparations for oral administration include tablets, capsules, granules, solutions, and suspensions. These formulations can be easily prepared by conventional methods.
薬学的に許容し得る賦形剤としては、例えばゼラチン、
乳糖、ブドウ糖、塩化ナトリウム、デンプン、ステアリ
ン酸マグネシウム、タルク、植物油、或いは他の医薬用
賦形剤が挙げられる。Pharmaceutically acceptable excipients include, for example, gelatin,
Examples include lactose, glucose, sodium chloride, starch, magnesium stearate, talc, vegetable oil, or other pharmaceutical excipients.
本発明のベンゾピラン誘導体の投与量は、投与経路、剤
形、患者の症状などによって変動し得るか、通常0.
002〜2mg/kg体重、好ましくは0.01〜0.
2mg/kg体重の範囲である。The dosage of the benzopyran derivative of the present invention may vary depending on the route of administration, dosage form, patient's symptoms, etc., or is usually 0.
002-2 mg/kg body weight, preferably 0.01-0.
The range is 2 mg/kg body weight.
[実施例]
以下に、本発明を実施例および試験例により更に詳細に
説明する。[Examples] The present invention will be explained in more detail below using Examples and Test Examples.
実施例−1(製法1に基づく合成)
ミノ]−2H−ベンゾ[b] ピランの合成(第1段階
)
6−ジアツー3.4−ジヒドロ−2,2−ジメチル−ト
ランス−4−’[(N−シアノ−アセトイミドイル)ア
ミノコ−2H−ベンゾ−[b] −ピラン−3−オール
17.25gをピリジン130m1に溶かし、水冷下で
撹拌しながら、R45O2Xとしてメタンスルホニルク
ロライド9.0gを加え、4時間反応する。反応混合物
を氷水中に注ぐと固化物が析出する。その固化物を濾取
し、エタノールから再結晶すると28.!5gの標題化
合物が結晶として得られる。Example-1 (synthesis based on production method 1) Synthesis of mino]-2H-benzo[b]pyran (first step) 6-diatwo-3,4-dihydro-2,2-dimethyl-trans-4-'[( 17.25 g of N-cyano-acetimidoyl)aminoco-2H-benzo-[b]-pyran-3-ol was dissolved in 130 ml of pyridine, and while stirring under water cooling, 9.0 g of methanesulfonyl chloride was added as R45O2X. React for 4 hours. When the reaction mixture is poured into ice water, a solidified substance precipitates out. The solidified product is filtered and recrystallized from ethanol.28. ! 5 g of the title compound are obtained as crystals.
融点 202〜204℃ NMR(CDCla)δ: 1.38 (s、3H)、1.56 (s、3H)。Melting point: 202-204℃ NMR (CDCa) δ: 1.38 (s, 3H), 1.56 (s, 3H).
2、41 (s、 3H) 、 3. 15 (t
、 3H) 。2, 41 (s, 3H), 3. 15 (t
, 3H).
4.82 (d、IH)、5.46 (t、LH)。4.82 (d, IH), 5.46 (t, LH).
6.90 (d、IH)、7.27〜7.61(m、3
H)
ベンゾ[b] ピラン(R’ =H,R1=Me、Y金
属アルコキシドであるカリウム tert−ブチラード
9.3gをジメチルホルムアミド60m1に溶解し、
(1)で得られた6−シアツー3.4−ジヒドロ−3−
メタンスルホニルオキシ−2,2−ジメチル−トランス
−4−[(N−シアノ−アセトイミドイル)アミノ]
−2H−ベンゾ[b] ピラン 3.Ogを加えて、室
温で4時間撹拌する。反応混合物を氷水150m1の中
に加えて、希塩酸にてpH2〜3にする。その後、酢酸
エチル200m1にて抽出し、飽和食塩水で2回洗浄し
た後、芒硝にて乾燥する。減圧下、酢酸エチルを留去す
る。残留固形物をベンゼン−酢酸エチル(1: 1)5
0mlから再結晶すると、1.9gの標題化合物が結晶
として得られる。6.90 (d, IH), 7.27-7.61 (m, 3
H) Benzo[b]pyran (R' = H, R1 = Me, Y metal alkoxide potassium tert-butylade 9.3 g was dissolved in 60 ml of dimethylformamide,
6-cya2-3,4-dihydro-3- obtained in (1)
Methanesulfonyloxy-2,2-dimethyl-trans-4-[(N-cyano-acetimidoyl)amino]
-2H-benzo[b]pyran 3. Add Og and stir at room temperature for 4 hours. The reaction mixture is added to 150 ml of ice water and brought to pH 2-3 with dilute hydrochloric acid. Thereafter, the mixture was extracted with 200 ml of ethyl acetate, washed twice with saturated brine, and dried over Glauber's salt. Ethyl acetate is distilled off under reduced pressure. The residual solid was dissolved in benzene-ethyl acetate (1:1)5
Recrystallization from 0 ml gives 1.9 g of the title compound as crystals.
融点 214〜215℃
NMR(DMSO−da )δ:
1、 50 (s、 3H) 、 2. 52 (s
、 3H) 。Melting point 214-215°C NMR (DMSO-da) δ: 1, 50 (s, 3H), 2. 52 (s
, 3H).
6、 23 (s、 IH) 、 6.87 (d、
IH) 。6, 23 (s, IH), 6.87 (d,
IH).
7.48 (dd、IH)、7.60 (d、IH)。7.48 (dd, IH), 7.60 (d, IH).
9.30 (b、LH)
実施例−2〜16
出発物質を種々変えて実施例−1と同様にして反応を行
ない、製法1に基づいて本発明のベンゾピラン誘導体を
得た。9.30 (b, LH) Examples 2 to 16 The reaction was carried out in the same manner as in Example 1 with various starting materials, and the benzopyran derivative of the present invention was obtained based on Production Method 1.
得られた実施例2〜16の化合物の構造式(R1、R2
およびYの置換基の種類)、それらの融点およびNMR
分析結果を第1表に示す。Structural formulas (R1, R2
and types of substituents of Y), their melting points and NMR
The analysis results are shown in Table 1.
(以下余白)
実施例−17
実施例−1(1)と同様にして6−ジアツー3.4−ジ
ヒドロ−3−メタンスルホニルオキシ−2,2−ジメチ
ル−トランス−4−[(N−シアノ−アセトイミドイル
)アミノ] −2H−ベンゾ[b] ピランを得、この
化合物 15gにベンゼン 3001、続いて有機塩基
として1.8−ジアザビシクロ[5,4,0] −7−
ウンデセン18gを加え、還流下で3時間反応し、反応
混合物を室温まで冷却後、酢酸エチル 2001を加え
て希釈し、この後、水で3回洗浄する。抽出液のベンゼ
ン−酢酸エチルを芒硝にて乾燥する。減圧下、ベンゼン
−酢酸エチルを留去する。(The following is a blank space) Example-17 In the same manner as in Example-1 (1), 6-dia2-3,4-dihydro-3-methanesulfonyloxy-2,2-dimethyl-trans-4-[(N-cyano- Acetimidoyl)amino]-2H-benzo[b]pyran was obtained, and 15 g of this compound was treated with benzene 3001 followed by 1,8-diazabicyclo[5,4,0]-7- as an organic base.
Add 18 g of undecene and react under reflux for 3 hours. After cooling the reaction mixture to room temperature, it is diluted by adding ethyl acetate 2001, and then washed three times with water. The benzene-ethyl acetate extract was dried with Glauber's salt. Benzene-ethyl acetate is distilled off under reduced pressure.
残留固形物をエタノールから再結晶すると9゜3gの標
題化合物が結晶として得られる。Recrystallization of the residual solid from ethanol gives 9.3 g of the title compound as crystals.
融点:214〜215℃ NMR(DMSO−da 1.50 (s、3H)。Melting point: 214-215℃ NMR (DMSO-da 1.50 (s, 3H).
6.23 (s、IH)。6.23 (s, IH).
7.48 (dd、IH) 9.30 (b、IH) 実施例−18 )δ: 2.52 (s、3H)。7.48 (dd, IH) 9.30 (b, IH) Example-18 ) δ: 2.52 (s, 3H).
6.87 (d、IH)。6.87 (d, IH).
、7.60 (d、IH)。, 7.60 (d, IH).
実施例−1(2)で得られた6−ジアツー2゜2−ジメ
チル−4−[(N−シアノ−アセトイミドイル)アミノ
コ−2H−ベンゾ[b] ピラン6、Ogをアセトニト
リル 2001に懸濁し、炭酸カリウム 6.12g、
ヨウ化カリウム 0゜75g1およびR5−Xとしてエ
チルブロムアセテート 7.53gを加えて還流下で2
時間撹拌する。その後、反応混合物を冷却後濾過して不
溶物の炭酸カリウム、臭化カリウムを除き、濾液中のア
セトニトリルを減圧下で留去する。残留物を酢酸エチル
2501に溶解し、飽和食塩水で洗浄した後、酢酸エ
チルを芒硝にて乾燥する。減圧下、酢酸エチルを留去す
る。6-Dia-2゜2-dimethyl-4-[(N-cyano-acetimidoyl)aminoco-2H-benzo[b]pyran 6, Og obtained in Example-1 (2) was suspended in acetonitrile 2001. , potassium carbonate 6.12g,
0.75 g of potassium iodide and 7.53 g of ethyl bromoacetate as R5-X were added and the mixture was heated under reflux.
Stir for an hour. Thereafter, the reaction mixture is cooled and filtered to remove insoluble potassium carbonate and potassium bromide, and acetonitrile in the filtrate is distilled off under reduced pressure. The residue was dissolved in ethyl acetate 2501, washed with saturated brine, and then the ethyl acetate was dried over Glauber's salt. Ethyl acetate is distilled off under reduced pressure.
残留固形物を酢酸エチル−n−へキサンから再結晶する
と4.8gの標題化合物が結晶として得られる。The residual solid is recrystallized from ethyl acetate-n-hexane to give 4.8 g of the title compound as crystals.
融点=180〜182℃ NMR(DMSO−da ) δ: 1.31 (t、3H)、1.54 (s、6H)。Melting point = 180-182℃ NMR (DMSO-da) δ: 1.31 (t, 3H), 1.54 (s, 6H).
2.36 (s、3H)、3.79 (d、IH)。2.36 (s, 3H), 3.79 (d, IH).
4.24 (q、2H)、4.70 (d、IH)。4.24 (q, 2H), 4.70 (d, IH).
6.08 (s、LH)、6.94 (d、IH)。6.08 (s, LH), 6.94 (d, IH).
7.31 (d、IH)、7.53 (dd、IH)実
施例−19〜39
出発物質、R5−Xを種々変えて実施例−18と同様に
して反応を行ない、製法5に基づいて本発明のベンゾピ
ラン誘導体を得た。7.31 (d, IH), 7.53 (dd, IH) Examples 19 to 39 The reaction was carried out in the same manner as in Example 18 with various starting materials, R5-X, and based on Production Method 5. A benzopyran derivative of the present invention was obtained.
得られた実施例19〜39の化合物の構造式(R1、R
2およびYの置換基の種類)、それらの融点およびNM
R分析結果を第2表に示す。The structural formulas (R1, R
2 and types of substituents of Y), their melting points and NM
The R analysis results are shown in Table 2.
(以下余白)
実施例−40
成
実施例−1(2)で得られた6−ジアツー2゜2−ジメ
チル−4−[(N−シアノ−アセトイミドイル)アミノ
コ−2H−ベンゾ[b] ピラン4、Ogをピリジン
601に溶解し、氷冷下で、R3−Co−Xとしてアセ
チルクロライド 1゜77gを反応液に滴下する。反応
混合物を水冷下で2.5時間撹拌した後、氷水 250
m1を加えると固形物が析出するので、この析出物を濾
過、水洗し、乾燥する。(Leaving space below) Example 40 6-Dia-2゜2-dimethyl-4-[(N-cyano-acetimidoyl)aminoco-2H-benzo[b]pyran obtained in Example 1 (2) 4. Og to pyridine
601, and 1.77 g of acetyl chloride as R3-Co-X was added dropwise to the reaction solution under ice-cooling. The reaction mixture was stirred for 2.5 hours under water cooling, and then poured with ice water at 250 ml.
When m1 is added, a solid precipitates out, and this precipitate is filtered, washed with water, and dried.
得られた固形物を酢酸エチルから再結晶すると3.4g
の標題化合物が結晶として得られる。When the obtained solid was recrystallized from ethyl acetate, 3.4 g
The title compound is obtained as crystals.
融点:214.5〜216℃
NMR(DMSO−ds ) δ;
1、 56 (s、 6H) 、 2−29 (s、
3H) 。Melting point: 214.5-216°C NMR (DMSO-ds) δ; 1, 56 (s, 6H), 2-29 (s,
3H).
2.91 (s、3H)、5.71 (s、LH)
。2.91 (s, 3H), 5.71 (s, LH)
.
6.90 (s、IH)、7.03 (d、IH)。6.90 (s, IH), 7.03 (d, IH).
7.51 (dd、LH)
実施例−41〜46
出発物質、R3−Co−Xを種々変えて実施例=40と
同様にして反応を行ない、製法6に基づいて本発明のベ
ンゾピラン誘導体を得た。7.51 (dd, LH) Examples 41 to 46 The reaction was carried out in the same manner as in Example 40 with various starting materials, R3-Co-X, to obtain benzopyran derivatives of the present invention based on Production Method 6. Ta.
得られた実施例−41〜46の化合物の構造式(R1、
R2およびYの置換基の種類)、それらの融点およびN
MR分析結果を第3表に示す。The structural formulas (R1,
types of substituents of R2 and Y), their melting points and N
The MR analysis results are shown in Table 3.
(以下余白)
実施例−47
まず、6−メドキシカルボニルー3.4−ジヒドロ−2
,2−ジメチル−4−[(N−シアノ−アセトイミドイ
ル)アミノコ−2H−ベンゾ[b]ピラン−3−オール
24.0gをピリジン100I111に溶かし、水冷
下で攪拌しながら、メタンスルホニルクロライド 17
.3gを加え、水冷下で40分間攪拌する。次いで反応
温度を室温に上げ、さらに2時間反応する。反応混合物
を氷水中に注ぐと固化物が析出する。その固化物を濾取
し、酢酸エチルから再結晶すると、30. ogの6
−メドキシカルボニルー3,4−ジヒドロ−3−メタン
スルホニルオキシ−2,2−ジメチル−4−[(N−シ
アノ−アセトイミドイル)アミノコ−2H−ベンゾ[b
] ピランが得られる。(Left below) Example 47 First, 6-medoxycarbonyl-3,4-dihydro-2
,2-dimethyl-4-[(N-cyano-acetimidoyl)aminoco-2H-benzo[b]pyran-3-ol 24.0g was dissolved in pyridine 100I111, and while stirring under water cooling, methanesulfonyl chloride 17
.. Add 3 g and stir for 40 minutes under water cooling. Then, the reaction temperature is raised to room temperature and the reaction is continued for an additional 2 hours. When the reaction mixture is poured into ice water, a solidified substance precipitates out. The solidified product was collected by filtration and recrystallized from ethyl acetate. og no 6
-Medoxycarbonyl-3,4-dihydro-3-methanesulfonyloxy-2,2-dimethyl-4-[(N-cyano-acetimidoyl)aminoco-2H-benzo[b
] Piran is obtained.
次に、この6−メドキシカルボニルー3,4−ジヒドロ
−3−メタンスルホニルオキシ−2,2=ジメチル−4
−[(N−シアノ−アセトイミドイル)アミノ3−2H
−ベンゾ[b] ピラン30、Ogを無水ベンゼン 5
80m1に溶かし、これに1,8−ジアザビシクロ[5
,4,0]7−ウンデセン 37.0gを加え、攪拌し
ながら2時間40分間攪拌する。反応液を冷却後、容量
が約1/3になるまで濃縮した後、酢酸エチル2.0f
lで希釈する。これを水、飽和食塩水の順で洗浄し、次
いで硫酸ナトリウムで乾燥した後溶媒を留去する。残渣
をシリカゲルカラムクロマトグラフィー(展開溶媒;塩
化メチレン−酢酸エチル=2 : 1)に付して精製す
ると、16.0gの6−メドキシカルボニルー2,2−
ジメチル−4−[(N−シアノ−アセトイミドイル)ア
ミノコ−2H−ベンゾ[b] ピラン(一般式[■コに
おいてR’ =H,R’ =MeSY=メトキシカルボ
ニルの化合物)が白色結晶として得られる。Next, this 6-medoxycarbonyl-3,4-dihydro-3-methanesulfonyloxy-2,2=dimethyl-4
-[(N-cyano-acetimidoyl)amino 3-2H
-benzo[b]pyran 30, Og anhydrous benzene 5
Dissolve in 80ml and add 1,8-diazabicyclo[5
,4,0]7-undecene (37.0 g) was added, and the mixture was stirred for 2 hours and 40 minutes. After cooling the reaction solution, it was concentrated until the volume became about 1/3, and then 2.0 f of ethyl acetate was added.
Dilute with l. This is washed successively with water and saturated brine, then dried over sodium sulfate, and the solvent is distilled off. The residue was purified by silica gel column chromatography (developing solvent: methylene chloride-ethyl acetate = 2:1) to yield 16.0 g of 6-medoxycarbonyl-2,2-
Dimethyl-4-[(N-cyano-acetimidoyl)aminoco-2H-benzo[b]pyran (a compound of the general formula [■ in which R' = H, R' = MeSY = methoxycarbonyl) was obtained as white crystals. It will be done.
融点:193〜195℃
NMR(CDC13)δ:
1.49 (s、6H)、2.54 (s、3H)
。Melting point: 193-195°C NMR (CDC13) δ: 1.49 (s, 6H), 2.54 (s, 3H)
.
3.84 (s、3H)、6.32 (s、IH)
。3.84 (s, 3H), 6.32 (s, IH)
.
6.85 (d、IH)、7.82 (m、2H)
このようにして得られた6−メドキシカルボニルー2,
2−ジメチル−4−[(N−シアノ−アセトイミドイル
)アミノコ−2H−ベンゾ[blピラン 5g (16
,7mmol )をメタノール200m1に溶解した後
、0℃に冷却する。これに飽和水酸化リチウム水溶液
60m1を加え、室温で17時間撹拌する。反応混合物
を25%リン酸二水素ナトリウム水溶液400mlに注
ぎ込んで中和した後、酢酸エチル 11で抽出する。抽
出液を水、飽和食塩水で順次洗った後、無水硫酸ナトリ
ウムで乾燥し、溶媒を留去する。6.85 (d, IH), 7.82 (m, 2H)
6-Medoxycarbonyl-2 obtained in this way,
2-dimethyl-4-[(N-cyano-acetimidoyl)aminoco-2H-benzo[blpyran 5g (16
, 7 mmol) in 200 ml of methanol and then cooled to 0°C. Add to this a saturated lithium hydroxide aqueous solution.
Add 60 ml and stir at room temperature for 17 hours. The reaction mixture was neutralized by pouring it into 400 ml of 25% aqueous sodium dihydrogen phosphate solution, and then extracted with 11 portions of ethyl acetate. The extract is washed successively with water and saturated brine, dried over anhydrous sodium sulfate, and the solvent is distilled off.
得られた白色粉末を酢酸エチル−ヘキサン(5:1)で
洗浄後、乾燥することにより、4.7g(収率98%)
の標題化合物を得る。The obtained white powder was washed with ethyl acetate-hexane (5:1) and dried to give 4.7 g (yield 98%).
The title compound is obtained.
融点=194〜196℃
NMR(DMSO−da )δ:
1、40 (s、 6H) 、 2.40 (s、
3H) 。Melting point = 194-196°C NMR (DMSO-da) δ: 1,40 (s, 6H), 2.40 (s,
3H).
6.08 (s、IH)、6.98 (d、IH)。6.08 (s, IH), 6.98 (d, IH).
7.82 (s、IH)、7.92 (dd、IH)実
施例−48
実施例−47と同様にして得た6−カルボキシ−2,2
−ジメチル−4−[(N−シアノ−アセトイミドイル)
アミノ] −2H−ベンゾ[b] ピラン 5.6g
(19,6mmol )をテトラヒドロフラン 120
1とアセトニトリル 120m1との混合溶媒に溶解し
た後、0℃に冷却する。これにジシクロへキシルカルボ
ジイミド 8.0g(39,3mmol )を加え、1
5分間撹拌した後、モルホリン 5. 1g (58,
9rrowol )を加え、さらに室温で4時間撹拌す
る。反応混合物を酢酸エチル 5001で希釈し、水、
30%リン酸二水素ナトリウム水溶液、飽和食塩水で順
次洗った後、無水硫酸ナトリウムで乾燥する。7.82 (s, IH), 7.92 (dd, IH) Example-48 6-carboxy-2,2 obtained in the same manner as Example-47
-dimethyl-4-[(N-cyano-acetimidoyl)
Amino]-2H-benzo[b]pyran 5.6g
(19.6 mmol) in tetrahydrofuran 120
After dissolving in a mixed solvent of 1 and 120 ml of acetonitrile, the solution was cooled to 0°C. 8.0 g (39.3 mmol) of dicyclohexylcarbodiimide was added to this, and 1
After stirring for 5 minutes, morpholine 5. 1g (58,
9 rrowol) and further stirred at room temperature for 4 hours. The reaction mixture was diluted with ethyl acetate 5001, water,
After sequentially washing with 30% aqueous sodium dihydrogen phosphate solution and saturated brine, drying over anhydrous sodium sulfate.
溶媒を留去後、残渣をシリカゲルカラムクロマトグラフ
ィー(展開溶媒:酢酸エチル、シリカゲル 150g)
で精製して、標題化合物の白色粉末3.6g(収率52
%)を得る。After distilling off the solvent, the residue was subjected to silica gel column chromatography (developing solvent: ethyl acetate, 150 g of silica gel).
to give 3.6 g of the title compound as a white powder (yield: 52
%).
融点=126〜128℃
NMR(DMSO−da )δ:
1、44 (s、 6H) 、 2.42 (s、
3H) 。Melting point = 126-128°C NMR (DMSO-da) δ: 1,44 (s, 6H), 2.42 (s,
3H).
3.49 (brs、4H)、3.60 (brs。3.49 (brs, 4H), 3.60 (brs.
4H) 、 5. 96 (s、 IH) 、 6
.86 (d。4H), 5. 96 (s, IH), 6
.. 86 (d.
IH) 、 7. 18 (d、 IH) 、 7
. 25 (dd、IH)、10.06 (brs、I
H)実施例−49
実施例−47と同様にして得た6−カルボキシ−2,2
−ジメチル−4−[(N−シアノ−アセトイミドイル)
アミノコ−2H−ベンゾ[b] ピランとジエチルアミ
ンとを実施例−48と同様に反応させて、製法8に基づ
いて標題化合物を得た。IH), 7. 18 (d, IH), 7
.. 25 (dd, IH), 10.06 (brs, I
H) Example-49 6-carboxy-2,2 obtained in the same manner as Example-47
-dimethyl-4-[(N-cyano-acetimidoyl)
Aminoco-2H-benzo[b]pyran and diethylamine were reacted in the same manner as in Example 48 to obtain the title compound based on Production Method 8.
融点:184〜186℃ NMR(DMSO−da )δ: 1.15 (t、6H)、1.43 (s、6H)。Melting point: 184-186℃ NMR (DMSO-da) δ: 1.15 (t, 6H), 1.43 (s, 6H).
2、 54 (s、 3H) 、 3. 34 (
m、 4H) 。2, 54 (s, 3H), 3. 34 (
m, 4H).
6、 00 (s、 IH) 、 6. 64 (
d、 IH) 。6, 00 (s, IH), 6. 64 (
d, IH).
6.84 (d、IH)、6.97 (dd、IH)9
、 79 (s、 IH)
実施例−50
基づく合成
実施例−47と同様にして得た6−カルボキシ−2,2
−ジメチル−4−[(N−シアノ−アセトイミドイル)
アミノコ−2H−ベンゾ[b] ピランとメタノールと
を、塩化水素の存在下で反応させて、製法9に基づいて
標題化合物を得た。6.84 (d, IH), 6.97 (dd, IH)9
, 79 (s, IH) 6-carboxy-2,2 obtained in the same manner as Synthesis Example-47 based on Example-50
-dimethyl-4-[(N-cyano-acetimidoyl)
Aminoco-2H-benzo[b]pyran and methanol were reacted in the presence of hydrogen chloride to yield the title compound based on Preparation 9.
融点=193〜195℃
NMR(DMSO−ds )δ:
1、49 (s、 6H) 、 2. 54 (s
、 3H) 。Melting point = 193-195°C NMR (DMSO-ds) δ: 1,49 (s, 6H), 2. 54 (s
, 3H).
3、 84 (s、 3H) 、 6. 32 (s
、 LH) 。3, 84 (s, 3H), 6. 32 (s
, LH).
6、85 (d、 LH) 、 7.82 (m、
2H)次に本発明化合物の効果を試験例にて説明す
る。6,85 (d, LH), 7.82 (m,
2H) Next, the effects of the compounds of the present invention will be explained using test examples.
試験例−1カリウムチャンネル活性化作用体重的240
gの雄性ウィスター系ラットの大動脈を摘出し、リング
状標本とし、95%酸素十5%炭酸ガスの混合ガスで飽
和したタレブスφヘンセレイト液(37℃)中に0.5
gの負荷をかけて懸垂し、20mMあるいは60mMの
塩化カリウムを加え、収縮反応をアイソメトリックトラ
ンスジューサー(日本光電社製)を介して測定した。塩
化カリウムの収縮反応が最大に達したら本発明化合物を
累積的に加え、弛緩反応を測定した。Test example-1 Potassium channel activation effect weight 240
The aorta of a male Wistar rat of 0.5 g was removed, made into a ring-shaped specimen, and placed in Talebs φ Henseleit solution (37°C) saturated with a gas mixture of 95% oxygen and 15% carbon dioxide.
The specimen was suspended under a load of 1.5 g, 20 mM or 60 mM potassium chloride was added, and the contraction reaction was measured using an isometric transducer (manufactured by Nihon Kohden). When the contraction reaction of potassium chloride reached the maximum, the compound of the present invention was added cumulatively, and the relaxation reaction was measured.
薬物による弛緩反応を、塩化カリウムによる最大収縮に
対する弛緩率として求めた。The relaxation response induced by the drug was determined as the relaxation rate relative to the maximum contraction induced by potassium chloride.
その結果を第4表に示す。The results are shown in Table 4.
(以下余白)
試験例−2血圧低下作用
20週齢の雄性自然発症高血圧ラット(SHR)を用い
、SHRを保定器に入れ45℃の加温箱で5分間加温す
る。5分間加温したSHRを測定用板に固定し、尾に加
圧および血圧測定用カフを取り付ける。加圧を開始する
と共に心拍数を測定する。ラットが安静になるのを待ち
、最高血圧を測定した。(Blank below) Test Example 2 Blood Pressure Lowering Effect Using a 20-week-old male spontaneously hypertensive rat (SHR), the SHR was placed in a retainer and heated in a 45°C heating box for 5 minutes. The SHR heated for 5 minutes is fixed on a measurement plate, and a cuff for pressurization and blood pressure measurement is attached to the tail. Begin pressurization and measure heart rate. After waiting for the rat to rest, systolic blood pressure was measured.
一方、本発明化合物を0.5%メチルセルロース溶液に
溶解あるいは懸濁し経口投与して、投与後1時間、3時
間、6時間に血圧測定した。On the other hand, the compound of the present invention was dissolved or suspended in a 0.5% methylcellulose solution and orally administered, and blood pressure was measured 1 hour, 3 hours, and 6 hours after administration.
投与前値からの変化率(%) その結果を第5表に示す。Rate of change from pre-administration value (%) The results are shown in Table 5.
(以下余白)
試験例−3毒性試験
急性毒性は体重22〜25gの雄性マウス10匹を1群
として用い、体重相応量を経口投与し、72時間後の死
亡率から面積法によりL−D5oを算出した。(Leaving space below) Test Example 3 Toxicity test Acute toxicity was determined by using 10 male mice weighing 22-25 g as a group, orally administering an amount appropriate to the body weight, and measuring L-D5o by area method based on the mortality rate after 72 hours. Calculated.
実施例−1で得られた本発明化合物のしD5oは200
0mg/kg以上であった。The D5o of the compound of the present invention obtained in Example-1 is 200
It was 0 mg/kg or more.
次に製剤例について説明する。Next, formulation examples will be explained.
製剤例−1 錠剤の製造 以下の成分を用いて、通常の方法により錠剤を得た。Formulation example-1 manufacturing of tablets Tablets were obtained by a conventional method using the following ingredients.
有効成分 (実施例1で得られた ll1g本発
明化合物)
乳糖
結晶セルロース
ステアリン酸マグネシウム
[発明の効果コ
以上詳述したとおり、本発明により、
50mg
00mg
3111g
優れたカ
リウムチャンネル活性化作用を有し、各種疾病の治療に
有効なベンゾピラン誘導体およびこのベンゾピラン誘導
体を含有する医薬組成物が提供された。Active ingredient (ll1g compound of the present invention obtained in Example 1) Lactose crystalline cellulose Magnesium stearate [Effects of the invention As detailed above, the present invention has an excellent potassium channel activating effect, A benzopyran derivative effective in treating various diseases and a pharmaceutical composition containing the benzopyran derivative have been provided.
Claims (2)
ル基、低級アルキニル基、ヒドロキシ低級アルキル基、
低級アルコキシ低級アルキル基、低級アルコキシカルボ
ニル低級アルキル基、ジ低級アルキルアミノ基、アラル
キル基、または基R^3−CO−(基中、R^3は低級
アルキル基、フェニル基、フェニル基が置換されていて
もよい低級アルケニル基または低級アルキニル基)を意
味し、R^2は水素、低級アルキル基、低級アルコキシ
低級アルキル基、フェニル基、またはアラルキル基を意
味し、Yはシアノ基、ハロゲン原子、ニトロ基、低級ア
ルキル基、低級アルキニル基、低級アルキルカルボニル
基、低級アルコキシ基、ジ低級アルキルアミノカルボニ
ル基、アリール基、低級アルコキシカルボニル基、カル
ボキシル基、またはモルホリノカルボニル基を意味する
。] で示される化合物またはその医薬上許容される塩。(1) General formula [I] ▲Mathematical formulas, chemical formulas, tables, etc.▼[I] [In the formula, R^1 is hydrogen, lower alkyl group, lower alkenyl group, lower alkynyl group, hydroxy lower alkyl group,
A lower alkoxy lower alkyl group, a lower alkoxycarbonyl lower alkyl group, a di-lower alkylamino group, an aralkyl group, or a group R^3-CO- (where R^3 is a lower alkyl group, a phenyl group, or a phenyl group substituted R^2 means hydrogen, a lower alkyl group, a lower alkoxy lower alkyl group, a phenyl group, or an aralkyl group, and Y represents a cyano group, a halogen atom, It means a nitro group, a lower alkyl group, a lower alkynyl group, a lower alkylcarbonyl group, a lower alkoxy group, a di-lower alkylaminocarbonyl group, an aryl group, a lower alkoxycarbonyl group, a carboxyl group, or a morpholinocarbonyl group. ] or a pharmaceutically acceptable salt thereof.
よび/またはその医薬上許容される塩を有効成分として
含有し、カリウムチャンネル活性化作用を有する医薬組
成物。(2) A pharmaceutical composition containing the compound of general formula [I] and/or its pharmaceutically acceptable salt according to claim (1) as an active ingredient, and having a potassium channel activating effect.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1-341528 | 1989-12-29 | ||
JP34152889 | 1989-12-29 | ||
JP2-73654 | 1990-03-23 | ||
JP7365490 | 1990-03-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH03279378A true JPH03279378A (en) | 1991-12-10 |
JP3037980B2 JP3037980B2 (en) | 2000-05-08 |
Family
ID=26414795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP02213530A Expired - Fee Related JP3037980B2 (en) | 1989-12-29 | 1990-08-10 | Benzopyran derivative |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3037980B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992019611A1 (en) * | 1991-04-26 | 1992-11-12 | Japan Tobacco Inc. | Novel benzopyran derivative |
-
1990
- 1990-08-10 JP JP02213530A patent/JP3037980B2/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992019611A1 (en) * | 1991-04-26 | 1992-11-12 | Japan Tobacco Inc. | Novel benzopyran derivative |
Also Published As
Publication number | Publication date |
---|---|
JP3037980B2 (en) | 2000-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200303303A (en) | Novel pyridine-and quinoline-derivatives | |
JPH10512896A (en) | Aryl and heteroaryl purine compounds | |
JP2002529467A (en) | Pyrazolopyrimidinone compounds effective in treating erectile dysfunction | |
JPH02502462A (en) | Compound | |
EP0719765A2 (en) | Phenylbenzimidazole derivatives | |
CS247073B2 (en) | Production method of 2-substituted 4-amino-6,7-dimethoxyghinolins | |
NO174050B (en) | ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE BENZOPYRANE COMPOUNDS | |
CN112920208B (en) | Boric acid-containing indole aryl sulfone derivative and preparation method and application thereof | |
JPH0574587B2 (en) | ||
NO151287B (en) | ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 9-HYDRAZONO-6,7,8,9-TETRAHYDRO-4H-PYRIDO (1,2-A) -PYRIMIDINE DERIVATIVES | |
JPS6028979A (en) | Imidazoquinazoline compound | |
JPH0139425B2 (en) | ||
EA009045B1 (en) | Process for producing acid adduct salt of polyacidic base compound | |
JPH03106875A (en) | 1-(3-pyridylmethyl)phthalazine derivative | |
JPS6222771A (en) | 5-substituted-6-aminopyrimidine derivative composition and use | |
JPH0377867A (en) | New oxazolopiperizine derivative | |
JPH03279378A (en) | Benzopyran derivative | |
JP2726999B2 (en) | Imidazo [2,1-b] benzothiazole derivatives and anti-ulcer agents containing the compounds as active ingredients | |
CN109761997B (en) | Preparation and application of bis-fluoroquinolone thiadiazole urea N-methyl lomefloxacin derivative | |
JP3223090B2 (en) | Phenylbenzimidazole derivative | |
JPH08183775A (en) | Trifluoromethylquinolinecarboxylic acid derivetive | |
JPS61205275A (en) | Novel 8-thiotetrahydroquinoline derivatives and salts | |
CN112574094B (en) | Indolone derivatives and pharmaceutical use thereof | |
JP3037979B2 (en) | Benzopyran derivative | |
BE898641A (en) | NEW CARBOXY-THIAZOLO (3,2-A) SUBSTITUTED PYRIMIDINES USEFUL IN PARTICULAR AS ANTIALLERGICS AND METHODS OF MAKING SAME |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
LAPS | Cancellation because of no payment of annual fees |